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ABSTRACT
Modern synthetic gene regulatory networks emerge from iterative design-build-test cy-
cles that encompass the decisions and actions necessary to design, build, and test target
genetic systems. Historically, such cycles have been performed manually, with limited
formal problem-definition and progress-tracking. In recent years, researchers have devoted
substantial effort to define and automate many sub-problems of these cycles and create
systems for data management and documentation that result in useful tools for solving
portions of certain workflows. However, biologists generally must still manually transfer
information between tools, a process that frequently results in information loss. Further-
more, since each tool applies to a different workflow, tools often will not fit together in a
closed-loop and, typically, additional outstanding sub-problems still require manual solu-
tions. This thesis describes an attempt to create a tool that harnesses many smaller tools to
automate a fully closed-loop decision-making process to design, build, and test synthetic
biology networks and use the outcomes to inform redesigns. This tool, called Phoenix,
inputs a performance-constrained signal-temporal-logic (STL) equation and an abstract ge-
netic-element structural description to specify a design and then returns iterative sets of
building and testing instructions. The user executes the instructions and returns the data
to Phoenix, which then processes it and uses it to parameterize models for simulation of
iv
the behavior of compositional designs. A model-checking algorithm then evaluates these
simulations, and returns to the user a new set of instructions for building and testing the next
set of constructs. In cases where experimental results disagree with simulations, Phoenix
uses grammars to determine where likely points of design failure might have occurred
and instructs the building and testing of an intermediate composition to test where failures
occurred. A design tree represents the design hierarchy displayed in the user interface
where progress can be tracked and electronic datasheets generated to review results. Users
can validate the computations performed by Phoenix by using them to create sets of classic
and novel temporal synthetic genetic regulatory functions in E. coli.
v
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1 Introduction
1.1 Synthetic Biology
The era of modern genetics began when Watson and Crick discovered the structure of
DNA in 195398, which laid the foundation for humans to understand heritable biological
information. After an additional twenty years of research focused on understanding the
mechanisms of nucleic acids, the first instance of genetic engineering was first reported32
in the literature. This breakthrough was enabled by development of techniques for cleaving
specific DNA strands with restriction enzymes93 and pasting cleaved strands back together
with DNA ligase100. This process of ‘DNA cut and paste’ paired with the technique of
DNA amplification via polymerase chain reactions (PCR)87 became the basis of modern
molecular cloning. The capabilities of molecular cloning technology have since developed
considerably to enable high-throughput DNA synthesis and custom DNA sequences for
modification.
At first, these molecular cloning techniques were largely used to clone single genes
or manipulate single genes of interest in a pre-existing natural genetic system. However,
around the turn of the millennium, multiple groups started exploring the idea of engineering
completely synthetic genetic systems from synthesized DNA. This materialized in the first
instances of synthetic transcriptional regulatory networks in E. coli40,47 and, consequently,
to the establishment of the field of synthetic biology. These first synthetic genetic reg-
ulatory networks galvanized many groups in the biology and biotechnology community
and inspired them to the create the first combinatorially-synthesized genetic networks49,
complex transcriptional-regulatory networks17,35,95,96 and RNA regulatory networks19,54.
Around this time, some of the first synthetic biology applications were also reported11,58,83
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and the biotechnology industry began to build around novel applications enabled by syn-
thetic biolog.
Towards the end of the 2000’s, as the techniques for engineering DNA improved and the
demand for DNA synthesis grew, an emphasis was placed on developing methodologies for
increasing the speed and scale of DNA synthesis42,48,62,81,90,99. These newer methodolo-
gies could be used to build larger and more complicated constructs at a higher throughput.
Concurrently, the community’s interest grew in applying ideas from other fields of engineer-
ing (specifically electrical engineering) to build these systems, and some synthetic biology
groups started building synthetic biology ‘logic gates’12,97. The interest in cellular logic
has since grown26,69 and recently, DNA recombinases have also been adopted in many of
these systems as a means of creating digital logic and storing memory27,44,91.
1.2 Bio-Design Automation
In parallel with the developments in biochemical technologies, engineers and computer
scientists from other fields garnered interest in synthetic biology and began developing
computational tools for engineering these genetic systems. One of the first realizations of
scientists and engineers from this background was that there were few standards and little
documentation for engineering these systems. In response, multiple efforts began working
towards community standards15,29,41,46,57,94 for data models and data exchange. This effort
has recently gained more momentum45 and seen support and involvement from larger
government organizations50. Currently, some of the core requirements for representing
sequence information has been discussed at length and interest has shifted into establishing
standards for additional related sub-problems.
One of the foundations of other engineering fields is the definition and solving of
sub-problems in a large and complicated process. This ‘divide and conquer’ approach
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allows for the solving of small parts of a larger problem one piece at a time and allows for
specialists to tackle specific narrow problems of which they have considerable expertise.
After all necessary pieces are defined and solved, solutions for sub-problemcan be automated
and connected to solve a larger problem. The central conjecture of this approach to synthetic
biology is that the application of these core engineering concepts will accelerate synthetic
biology workflows and increase the scale of systems that can be successfully built. This
pursuit has recently been coined bio-design automation36.
The current bio-design automation landscape can be divided into fourmain areas: design
specification, DNA assembly planning and implementation, strain characterization and
analysis, and machine learning. ‘Design specification’ concerns a precise, formal definition
of the desired function and design of a target genetic system. ‘DNA assembly planning’
concerns the set of decisions needed to determine a plan for composingDNAconstructs from
their elements using specific cloning methodologies and ‘DNA assembly implementation’
refers to the processes and decisions involvedwith physically implementing aDNAassembly
plan. ‘Strain characterization and analysis’ concerns the design and physical implementation
of experiments for characterizing engineered strains and the accompanying analysis and
interpretation of acquired data. ‘Machine learning’ concerns the automated revision of
design based upon processed experimental outcomes.
1.2.1 Design Specification
Design specification concerns can be broken down into at least the following six sub-
-problems: 1. Formal specification; 2. Data model and mathematical model definition;
3. Simulation and verification; 4. DNA library definition; 5. Part assignment; 6. De-
sign hierarchy. In recent years, a number of formal design specification tools have been
introduced.
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Some tools focus on the structure and organizational aspects of design31,34,73,74,78,
which largely concentrates on part and device design in terms of organization and selection
of genetic elements. Other specification tools have put more emphasis on formal mathemat-
ically-defined functional specification20,103, although tools of this type have not yet been
explored in great depth.
Since every computational tool relies on a data model, several synthetic biology commu-
nity datamodel standards have been developed46,101 with notable differences. But, given the
community emphasis on standardization, converters between many data models have been
implemented. The scope of mathematical models for describing and simulating synthetic
genetic systems is much larger and extends beyond the field of synthetic biology66,68,72 to
systems biology, in which more standard tools exist for mathematical model specification56.
Numerous commercial and open source tools exist for building and editing customDNA
sequences such as VectorNTI, Benchling, APE, and GenomeCompiler, but they generally
require users to upload specific DNA sequences as linear or circular fragments and cus-
tom-annotate them with sequence features. The most widely-adopted open-source format
for exchanging this data is GenBank, an open source format supported by NIH, although
other formats exist and have variable degrees of expressiveness. Since some features have
measurable parameters associated with them, they can be ported into simulation tools to
create simulated traces with a given mathematical model30,60. These traces can then be
used by model-checking tools to verify their function18,104.
The process of selecting features from feature libraries to apply to an abstracted genetic
regulatory network design (AGRN) is known as part assignment. Recent tools for part as-
signment topic have been developed88,102, but they do not tie in with verification tools. And,
with the vast options for AGRN design with numerous tools, there remain many unsolved
problems related to determining optimized part arrangements in AGRNs. Furthermore,
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these selections are heavily based on the assumptions in the underlying mathematical model
and experimental design, which is often variable and can make these tools hard to apply.
Finally, although there are some tools that integrate the idea of hierarchical design and
grammars to verify the validity of designs34,78, there aren’t any existing tools that decompose
a large design into its functional and structural hierarchy and tie these breakdowns to
mathematical models. Such a tool could be useful in unifying and organizing many of these
concerns, since many of them overlap.
In summary, there has been significant thought and tool development on a variety of
design specification problems, but there aren’t any tools that unify all of these topics in a
cohesive, meaningful way. Although data exchange standards have been developed, many
tools were created before many aspects of the current community standard were agreed
upon and in many cases, the older tools are no longer maintained, making them unusable
under the newer standards.
1.2.2 DNA Assembly
Once a target design specification has been mapped to a set of target DNA constructs, a
plan for how to assemble themmust be determined. This problem, called the DNA assembly
problem, has both design optimization and physical implementation aspects and can be
broken into at least these four sub-problems: 1. Cloning and synthesis method selection; 2.
Hierarchical assembly planning; 3. Primer design; 4. Physical implementation.
The set of all chemical reactions and flanking DNA sequence designs required to
assemble one or more DNA fragments into a replicating biological vector defines a cloning
method. Each cloning methods utilizes different enzymes, chemical reaction conditions,
and required flanking sequence regions around DNA fragments. In recent years, numerous
methods have been developed with variations in each of these categories42,48,62,81,89,90,99,
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but all have the goal of scaling and modularizing cloning capabilities. Some methods
place a heavy emphasis on modularity99 and standardization90, while others place a heavier
emphasis on the scale of fragments that can be reliably assembled48.
Once an assembly method is selected for a set of target constructs, the design questions
relating to assembly can be separated into hierarchical assembly planning and primer
design for PCR. Hierarchical assembly planning refers to the choice of which fragments to
put together in parallel and in series. For large assemblies or large sets of assemblies, it
is desirable that fragment re-use is maximized and the number of cloning steps required is
minimized to optimize cloning time and material expense. Some prior work has been done
on this topic25,37, although it was restricted to older cloning methods and did not include
options to account for many experimental concerns in the cloning process.
Once a plan for hierarchical assembly is determined, flanking regions for each of these
fragments must be determined and primers must be designed for PCR such that the correct
flanking regions are added to each fragment. This problem has been explored for many
contemporary cloningmethods52 andmany commercial sequence editors (mentioned above)
have integrated tools for these decisions. Many of the decisions on this level are sensitive
to cloning method and DNA chemistry and efficiency can be heavily impacted by small
changes in flanking region design.
After this series of decisions is made, all decisions required for assembly planning
have been made, except for detailed chemical protocols. The design of these protocols,
namely PCR, DNA preparation, DNA transformation and organism growth conditions
still has to be defined. Some of the required chemical protocols are standardized by
the chemical manufacturer, but many cloning reaction reagents are not yet available in
the form of a standard master mix with standard thermal reaction cycles. The problem
of how to execute all necessary protocols efficiently is the protocol planning problem.
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Some open-source63 and industrial tools have been created to address these problems and
automatically instruct liquid-handling robots to execute these tasks, removing the human
element from the assembly process in an effort to reduce human cost and improve protocol
reproducibility.
1.2.3 Strain Characterization
Physically-assembled DNA constructs must then be evaluated for function in the organ-
ism for which they were designed. The process of testing and evaluating synthetic DNA
constructs is called strain characterization. The characterization sub-problems include: 1.
Selection of measurement method and settings; 2. Definition of types of testing experiments
and associated context based on measurement method and settings; 3. Data analysis and
processing; 4. Data organization and visual representation.
In the bio-design automation field, the problem of formally selecting a measurement
method or set of methods and then defining standard testing experiment types and settings
is largely untouched and under-developed. This is likely due to the fact that bio-design
automation is relatively new and not widely known or accepted by experimentalists, and
even those who collaborate with pure experimental experts typically have little influence
over experimental design. Some groups have started to develop standard flow cytometry
protocols75, but this topic has not been explored in depth in the literature.
Analysis tools for experimental data are more numerous and mature. Specifically, the
synthetic biology community often uses single-cell fluorescence as the primary measure-
ment technique and there are a wide variety of open-source38,80 and industrial tools (BBN
Synbio Tools, FlowJo and BD FACSDiva) for analyzing single-cell fluorescence data. This
topic extends beyond the field of synthetic biology79,86 and principles and standards for this
type of data have been developed51,85.
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The problem of how to use this processed data to create intelligible graphs and present
this and other design information to a human designer is another open problem in the
bio-design automation field. In electrical engineering, data related to physical components
is represented in the form of a datasheet. In the synthetic biology field, the necessary
information for datasheets has began to be explored15,29 and some groups are working on
electronic datasheets, but it has yet to be demonstrated how these can be used meaningfully
to help human designers refine their designs.
1.2.4 Machine Learning
Automatically using characterization data to revise designs produced from design spec-
ifications can be classified as machine learning. These machine learning sub-problems are
the least developed and least defined in the bio-design automation space. There have been
some recent efforts that use machine learning to revise design92, but this space remains
small due to the fact that the learning algorithms are heavily based upon a deep understand-
ing of the experimental design of characterization experiments which tend to be highly
variable as discussed in the prior section.
1.3 Regulation and Biosecurity
The field of synthetic biology and bio-design automation are rapidly growing55 and
broadening their accessibility to international audiences. A large contributor to this rapid
and sustained growth is the International Genetically Engineered Machine (iGEM) com-
petition94. The first iGEM at MIT in 2004 included 5 teams from 5 US universities, and
has been steadily growing to over 280 teams from over 30 countries in 2015. Additionally,
other government-funded initiatives and projects such as the Synthetic Biology Project at
the Woodrow Wilson Center for Scholars and the Synthetic Biology Engineering Research
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Center Synberc have helped centralize the efforts of academic and industrial researchers,
social scientists and legal experts in the synthetic biology field, creating a small but diverse
and growing community.
This rapid growth has many positive impacts, namely building general excitement about
the positive aspects of synthetic biology technologies, building community, and creating
awareness of synthetic biology projects. However, with such fast growth of a field with a
small core and potentially revolutionary applications, the risks posed by synthetic biology
technologies and applications must be taken seriously. The broad adoption of personal
computing and internet technologies combined with the speed of the growth of the field has
enabled a massive amount of new information and capabilities to be very broadly accessible.
A substantial, rapid growth of powerful technologies poses a challenge to many regula-
tory agencies. Debating and creating legislation is a historically slow process and, currently,
the technological developments are greatly outpacing the regulatory framework. Recent
calls16,61,76 for regulatory agencies to get some of these technologies on their radar and
react to them quickly, but not irrationally, have began to open up the public forum on how to
address such issues. There is currently some pressure on international regulatory agencies
to begin thinking about these topics, but in many cases it is still unclear what risk is posed by
specific synthetic biology technologies, since very little risk-assessment research has been
funded in the field. Furthermore, given the diversity of sub-topics in synthetic biology and
the interdisciplinary nature of the field, there is still currently no widely adopted definition
of ‘synthetic biology’.
Although the bio-design automation sub-field is currently almost exclusively focused
on basic science research of the core basic research problems and not applications, the
long term vision is to automate many, if not all, of the decisions currently made to design
these systems and make it easier for people to engineering biology. This goal is noble
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in the lens of a pure scientist, but there are implications of making an already powerful,
accessible, and rapidly growing technology evenmore powerful and accessible. The specific
consequences are hard to predict, but given that regulatory agencies are already behind the
pace of the research, accelerating it even more could prove problematic. On the other hand,
transitioning the decisions-making processes of biologists entirely into the digital realm
creates unprecedented opportunities for documenting and tracking designs of synthetic
biology projects. Given the growing world of computing and cyber-security, it is possible
that principles of cyber-security could be incorporated into design tools to defend against
possible harmful uses of synthetic biology.
1.4 A Design-Build-Test-Learn Tool
With the progress of the bio-design community in identifying and building tools to
automate many necessary sub-problems of a synthetic biology design and implementation
process, the fast growth of the broader synthetic biology community, and the possible
implications of enabling an even broader community of biologists, now is the time to
develop a software tool that integrates these design sub-problems into a closed-loop de-
sign-build-test-learn cycle. Recent prior work has made efforts to automate the full process
of these cycles21,39,84, but no tool has been able to harness all the pieces of the workflow in
an integrated manner and some of the necessary sub-problems of these cycle have not yet
been defined and automated.
In this thesis dissertation, I detail my work in creating a design-build-test-learn tool for
design decisions in a synthetic biology workflow for creating synthetic genetic regulatory
networks in E. coli. I accomplish this by re-using or modifying existing tools for solved
sub-problems and identifying important sub-problems that have not seen much focus in
prior work and creating working solutions for them. I preface the discussion of this work
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with the discussion of additional biosecurity and biosafety work I did in collaboration with
the MIT PoET synthetic biology group and iGEM competition and analysis of regulatory
gaps and risk assessment posed by a possible synthetic biology application, RNA-guided
gene drives. It is my belief that these types of questions must be asked at the beginning
of technical research projects to inform the path of project development. It is my hope
that this body of work can both increase the scale and speed of synthetic biology and open
opportunities for applying solutions to broader problems that synthetic biology poses.
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2 Regulatory Gaps and Biosecurity
Synthetic biology is a unique field in the way that a central goal of all synthetic biology
efforts is to produce an organism or genetic system with novel capabilities. This poses a
problem because there is generally no precedent for novel engineered organisms or novel
genetic systems and there exists minimal bench-marking or definition to use as a reference
for determining risk. Furthermore, in addition to having no working reference point for
assessing risk, there has been very little work to date to attempt to determine risks posed by
specific applications. This problem is further complicated by the fact that these organisms
and genetic systems are generally designed to self-replicate, which implies that any harm
created by a synthetic biology application would be self-propagating and difficult to control.
With the lack of these reference points for risk, it is difficult to formmeaningful safety or
security regulations for synthetic biology-specific applications. Combinedwith the fast pace
of technical developments in synthetic biology relative to the pace of regulatory framework
development, most regulatory agencies are behind in the process of regulation formation for
synthetic biology-specific applications. This leaves the field in a state where although there
have yet to be any synthetic biology applications to cause major harm to consumers or the
environment, a problem could arise relatively quickly with any particular application and it
would be hard to predict or manage with the current sparse risk assessment and regulatory
infrastructure.
This under-developed infrastructure imposes both great power and great responsibility
to those people who are performing the technical work. Synthetic biologists have both
the power to develop potentially revolutionary technologies and applications to advance the
state of biotechnology and human health, and at the same time, the power to develop harmful
technologies either through either carelessness, malevolence, or inadequate methodologies
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to assess risk.
These problems would lead a responsible synthetic biologist to ask the following ques-
tions: ‘‘Which synthetic biology applications should I develop? Which applications should
I not develop? And why? And who will these applications impact?" My colleagues and I
are of the opinion that these questions should be asked at the outset of synthetic biology
application selection and development. The following section describes recent work we
have done in this frame of mind in the sub-fields of biosafety and biosecurity screening,
and, risk definition and regulatory gap identification for a potentially impactful synthetic
biology application - RNA-guided gene drives.
2.1 Biosecurity
The largest current open community of synthetic biologists are the participants of the
annual iGEM competition - an international synthetic biology project competition. The
iGEM organization has spent the past decade encouraging teams to push their projects to the
frontiers of synthetic biology. However, as the number of projects and their sophistication
increases, so does the level of assumed risk. To manage this risk it would be useful to be
able to adopt an existing international framework for assessing this risk. However, there is
one major problem - no such framework currently exists.
In the absence of a coherent international framework for evaluating these risks in
synthetic biology, iGEM has recently engaged with the MIT Program on Emerging Tech-
nologies (PoET) to develop a progressive approach for handling questions of safety and
security. These two groups have worked together to create a rigorous screening program,
acknowledging that a strengthened set of iGEM safety policies ultimately serves to expand,
not contract, the universe of acceptable projects. This section reports on the policy process
evolution thus far, screening findings from the 2013 competition, and expectations for future
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policy evolution.
Much like synthetic biology as a whole, iGEM has exploded in size, geographic scope,
and technical capabilities over the past ten years. While this growth is beneficial, it also
means that advancements have at times outpaced regulations. iGEM has reckoned with
this mismatch most directly on issues of biosafety and biosecurity. However, rather than
limiting projects’ scope to remain conservative in the face of uncertainty, iGEMhas engaged
directly with safety challenges. Working with MIT (PoET), iGEM Headquarters has begun
a multiyear process of developing progressive safety policies. This paper considers the
motivations behind these changes, highlights the growth of key partnerships and collabora-
tions, summarizes the 2013 safety screening findings, and looks ahead at opportunities for
continued policy evolution.
2.1.1 iGEM Biosafety Screening Background
In 2011 and 2012, iGEM implemented a standardized screening system for teams
safety forms. Prior to 2011, there was not a systematic review process in place. The
new form consisted of questions prompting teams to (1) consider possible environmental,
health, and safety implications of their projects and (2) provide sufficient information
about their projects and procedures so that the Safety Committee could identify potential
concerns. Before regionals, the MIT PoET group reviewed the forms, and projects that
raised concerns were examined by the iGEM Safety Committee. Screening thresholds were
set with a deliberate bias toward generating false positives as opposed to false negatives.
Completion of the safety form was a requirement for participation.
Comprehensive project screening revealed a series of near misses in the 2011 and
2012 seasons. In iGEM, these apparent near misses were a consequence of inaccurate
reporting. For example, one team improperly understood their project, reporting that they
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were using biological parts from an organism of concern in an insufficiently protective
laboratory environment. On further review, the Safety Committee determined that the team
had misclassified the biological parts with which they were working, and that the laboratory
was appropriate for the true level of risk associated with their project. Near misses can
serve as valuable sources of information for tracking potential weaknesses in a system, such
as here where the team had clearly been insufficiently informed as to how to differentiate
between safe and unsafe work.
The MIT PoET group used the results of two years of project screenings to propose
changes to the 2013 process. These revisions were the product of discussions with the Safety
Committee, faculty advisors, and iGEM Headquarters. The revisions aimed to shift the
point of intervention closer to the time when actual laboratory work was being performed,
such that potential hazards could be detected and prevented prior to a harmful event, rather
than after the high-risk work had already been completed (Figure 1).
In 2013, teams submitted forms describing safety procedures and project implications,
and also listed the chassis and parts used in their projects. If any parts or chassis were derived
frommammals or organisms above risk group level one, teams also completedmore detailed
forms addressing areas of potential concern. Here, ‘‘chassis" refers to a host organism, such
as Escherichia coli or Bacillus subtilis, into which a synthetic device is placed, while a
genetic ‘‘part" is a component of the device, such as a promoter or terminator. Risk
group assignments are based on the relative risk of the originating organism, as assigned
by organizations such as the World Health Organization5 and the U.S. National Institutes
of Health Recombinant DNA Guidelines3. Assignment of organism-level risk group to its
component parts is a conservative approach, but currently a necessary starting point due to
the limited state of regulations. Developing an expedited screening protocol based on part
functionality rather than organism of origin is a near-term goal.
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Deadlines were earlier than in previous years and forms were required to be updated to
reflect project changes, which facilitated intervention prior to teams conducting potentially
dangerous work. However, the 2013 update did not make the screening occur early enough,
as the majority of the process still took place beyond the point of maximum utility. This is a
policy priority for future years. The program succeeded more significantly on other fronts,
though, such as by instituting standardized data entry, requiring updated forms for relevant
project changes, and increasing the emphasis placed on consideration of parts’ functional
properties. The program also strived for increased participant engagement with safety
concerns and saw gains in the areas of more in-depth form reporting, team-driven shifts
in project scope due to safety concerns, and active participation with the Safety list-serve,
suggesting a desire to improve understanding rather than solely ticking check boxes.
Because of the process changes, participants had to be educated on risk group levels,
changes in risk due to genetic modifications, the relationship of part functions to risk group
assignments, and laboratory biosafety levels. However, as iGEM’s new policies outpaced
many international biosafety efforts, appropriate supporting educational documents had
yet to also evolve. Multiple stakeholders assisted iGEM in providing guidance. One
primary contributor was Public Health Canada, which aided in the development of the
updated screening criteria. Additionally, J. Christopher Anderson and Terry Johnson of
the University of California-Berkeley provided video instruction on traditional biological
risk assessments, as well as on understanding and defining responsible conduct in synthetic
biology.
2013 also marked the beginning of a collaboration between MIT PoET and iGEM with
Synthetic Genomics, Inc. (SGI). This partnership resulted in SGI applying its proprietary
screening tool, Archetype, to the entire iGEM Parts Registry. Archetype, which screens at a
higher level of detail than the International Gene Synthesis Consortium (IGSC) standards
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Figure 1: Advancing the point of intervention in biosafety screening. In 2011 and 2012, the safety
process was limited to screening after projects had been completed (right); in 2013, the screening
shifted closer to intervening during the design-build-test cycle (middle). Future iterations aim to
move intervention further up the chain to maximize safety (left).
require, validated previous screening efforts by revealing no concerns that the Safety Com-
mittee had not already flagged. The results of this screening were also used to set terms of
access to iGEM parts, and are providing an empirical basis for evaluating national regula-
tions and international agreements governing parts safety and security. Continuation of this
partnership through an annual screening of all newly submitted parts would institutionalize
a vital secondary check within the overall safety system.
2.1.2 2013 Findings
The 2013 collegiate-level safety screening involved the review of 184 wet-lab teams
before the regional jamborees. In a continuation of recent trends, the 2013 competition
again witnessed increased project complexity and higher possible risk exposure. Here, the
primary factors of safety concern-chassis risk group and part risk group are characterized
by region and overall. Comments regarding laboratory biosafety levels are also included.
Chassis
The safety screen recorded the highest reported risk group level of chassis used per
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project. For any efforts involving an organism above risk group level one, a Secondary
Form was also required. The vast majority of iGEM teams used chassis from the lowest
risk group level; across all competitors, 90% employed no higher than a risk group level
one chassis (Table 1).
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chassis part
risk group level 1 2 3 other 1 2 3 other
North America 92% 6% 0% 2% 56% 37% 0% 8%
Europe 86% 12% 0% 2% 59% 27% 2% 12%
Asia 90% 8% 0% 2% 52% 31% 3% 15%
Latin America 91% 9% 0% 2% 55% 31% 2% 12%
total 90% 9% 0% 2% 55% 31% 2% 12%
Table 1: Highest chassis and part risk group level per team, presented by region and in sum. ‘‘Other"
refers to areas of unresolvable assignment uncertainties.
Parts
The 2013 iGEM safety screen also required information on any new or modified
coding regions that teams were using in their projects. A Secondary Safety Form was
required for any part sourced from a risk group two or higher organism, or from a
mammal. Parts from the 2013 Distribution Kit were exempted from review. Overall,
55% of iGEM teams reported no use of parts from higher than a risk group level one or-
ganism (Table 1). A further 31% reported use of parts from risk group level two organisms.
Teams’ detailed reporting in the Basic and Secondary Forms allowed for intervention
on all serious concerns prior to the Jamborees. Though not every safety concern was fully
resolved, there were no last-minute surprises in 2013. The quality of reporting was mixed,
with some teams providing exemplary responses and demonstrating deep consideration of
the relevant issues, while others were either cursory in their efforts, or were uninformed
about their universities’ or countries’ biosafety regulations.
The most troubling mistake found across multiple forms was teams incorrectly asserting
that their universities had no Institutional Biosafety Committee or equivalent group. Teams’
home universities hold the key responsibility for ensuring sound laboratory practices, so a
lack of understanding of these resources and requirements is cause for concern, and should
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be a target for future educational efforts. The importance of home institutions serving
as the safety backbone of iGEM is reinforced by the self-reporting nature of the safety
policies. While standardized forms requesting specific data helped to improve reporting,
there remain no ready means for iGEM to ensure the veracity of statements provided.
Therefore, emphasizing compliance and consultation with home institutional biosafety
entities, which do have access to laboratories for verification purposes, helps to reduce
the uncertainty around responses provided. Further, planned improvements to guidance
documents will include better explanations of the intentions of various questions in the
coming year, and thus, the safety process should expect more informed responses.
2.1.3 Future Considerations
Changes made to the 2013 screening process marked an important step in the overall
evolution of safety policies within iGEM. However, improving safety at iGEM is an iterative
process, and lessons learned from 2013 will necessarily inform changes to the 2014 effort.
Of these modifications, the following are of top priority:
1. Pre-approval of projects exceeding certain risk thresholds. iGEM is striving to
attain points of intervention that optimize participant safety while maintaining project
flexibility (Figure 1). By requiring advance approval of plans to use organisms or
parts more likely to present hazards, iGEM aims to prevent situations such as those
in 2011-2013, in which teams worked with dangerous components before the safety
screeners were made aware of their plans and had an opportunity to act.
2. Improved clarity and guidance. Much remains unknown about how to assess risk
when organisms are broken down to component pieces. iGEM and collaborators have
attempted to provide guidance; however, significant room for improvement remains.
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Guidance documents must be produced concomitant with policy evolution in order
to provide clarity in this area.
3. Increased advisor involvement. The iGEM safety process relies on teams’ home
universities, and thus, active advisor involvement is vital. The 2014 process will
continue to work on facilitating communication and engagement with the overseeing
parties. A strengthened set of iGEM safety policies ultimately serves to expand the
universe of acceptable projects. By understanding areas of concern, and knowing
how to address them responsibly, teams are capable of working safely along the
technology frontier. Safety policies are evolving in pursuit of this goal, and with this
aim, safety at iGEM is pointing toward the future.
2.1.4 Continued Developments
In 2014 and 2015, safety screening policies in iGEM followed the outlined future
considerations from 2013. iGEM headquarters hired a full-time employee to handle the
safety screening process and held safety and security-specific meetings at the 2014 and
2015 iGEM giant jamborees to discuss specific projects that exposed new security and
safety concerns. Additionally, the yearly screening of sequences in the Registry by SGI was
continued and flagged appropriate sequences of concern.
In summary, the safety screening process in iGEM represents one of the most thorough
long-term efforts to evaluate synthetic biology designs for both sequence, function and
design objective. Although iGEM shifted from volunteer screeners to a full-time employee
dedicated to screening projects, these projects do not represent all synthetic biology projects
and will not scale as the research field continues to increase in size. In the future, there will
need to be automated tools for evaluating and flagging designs with respect to safety and
security to supplement these screening efforts.
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2.2 Risk Assessment and Regulatory Gaps
The iGEM safety screening process represents a methodology for identifying projects
that raise safety and security concerns. Once a project or application is identified, the risks
for that application must be assessed and it must be determined if the existing local and
global regulations are adequate for governing them.
Since many regulations that would be applied to synthetic biology applications were
created before the synthetic biology field existed, considerations for problems exposed by
synthetic biology technologies can be insufficient. In the case of RNA-guided gene drives
which strongly bias inheritance, my colleagues and I found this to be the case.
2.2.1 RNA-Guided Gene Drives
Genes in sexually reproducing organisms normally have, on average, a 50% chance
of being inherited, but some genes have a higher chance of being inherited. These genes
can increase in relative frequency in a population even if they reduce the odds that each
organism will reproduce. Aided by technological advances, scientists are investigating
how populations might be altered by adding, disrupting, or editing genes or suppressed by
propagating traits that reduce reproductive capacity28,43. Potential beneficial uses of such
‘‘gene drives" include reprogrammingmosquito genomes to eliminate malaria, reversing the
development of pesticide and herbicide resistance, and locally eradicating invasive species.
However, drives may present environmental and security challenges as well as benefits.
Gene drives are subject to two fundamental limitations. First, drives will only function
in sexually reproducing species, so they cannot be used to engineer populations of viruses
or bacteria. Second, a newly released drive will typically take dozens of generations to
affect a substantial proportion of a target population, unless drive-containing organisms are
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released in numbers constituting a substantial fraction of the population. The process may
require only a year or less for some invertebrates, but centuries for organisms with long
generation times.
Studies have evaluated the possibility of releasing transgenic mosquitoes to combat the
spread of malaria, dengue, and other mosquito-borne diseases, including requirements for
containment, testing, controlled release, and monitoring of mosquito gene drives. This
work will need to be replicated and extended for proposed gene drives seeking to alter other
species22,67. It is crucial that this rapidly developing technology continue to be evaluated
before its use outside the laboratory becomes a reality.
2.2.2 Technical Developments
One promising method for creating a gene drive uses targeted endonuclease enzymes to
cut a specific site in the DNA of the organism. In organisms that inherit one chromosome
with this enzyme’s gene and one without it, the endonuclease will cut the latter, inducing the
cell to copy the endonuclease and surrounding genes onto the chromosome that previously
lacked them (Figure 2). Ten years ago, Burt proposed using endonuclease drives to spread
traits that would control diseases borne by insect vectors28. He suggested that drives could
be designed to add or delete genes and suppress populations, potentially to the point of
extinction. However, no drive capable of spreading efficiently through a wild population
has yet been developed. A major reason has been the difficulty of programming drives to
cut desired sequences at high efficiency.
Scientists recently developed a powerful and efficient tool for genome engineering that
uses the CRISPR nuclease Cas9 to cut sequences specified by guide RNA molecules33,67.
This technique is in widespread use and has already engineered the genomes of more than
a dozen species. Cas9 may enable ‘‘RNA-guided gene drives" to edit nearly any gene in
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Figure 2: How endonuclease gene drives spread altered genes through populations. (a) Altered
genes (blue) normally have a 50% chance of being inherited by offspring when crossed with a
wild-type organism (gray). (b) Gene drives can increase this chance to nearly 100% by cutting
homologous chromosomes lacking the alteration, which can cause the cell to copy the altered gene
and the drive when it fixes the damage. (c) By ensuring that the gene is almost always inherited,
the gene drive can spread the altered gene through a population over many generations, even if the
associated trait reduces the reproductive fitness of each organism. The recently developed CRISPR
nuclease Cas9, now widely used for genome engineering, may enable scientists to drive genomic
changes that can be generated with Cas9 through sexually reproducing organisms (1).
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sexually reproducing populations43.
To reduce potential negative effects in advance of construction and testing, Esvelt et
al. have proposed several novel types of drives43. Precision drives could exclusively
affect particular species or subpopulations by targeting sequences unique to those groups.
Immunizing drives could block the spread of unwanted gene drives by preemptively altering
target sequences. Reversal drives could overwrite unwanted changes introduced by an
initial drive or by conventional genome engineering, even restoring the original sequence.
However, ecological effectswould not necessarily be reversed. These and otherRNA-guided
gene drives have yet to be demonstrated in the laboratory.
2.2.3 Environmental and Security Aspects
A recent workshop examined key questions concerning effects of development and use
of gene drives in varied species and contexts10,59.
Targeted wild organisms.
Scientists have minimal experience engineering biological systems for evolutionary
robustness. Drive-induced traits and altered population dynamics must be carefully
evaluated with explicit attention to stability. For example, a drive may move through only
part of a population before a mutation inactivates the engineered trait. In some cases,
preferred phenotypes might be maintained as long as new drives encoding updates are
periodically released. The effects of a strategy dependent on repeatedly releasing drives to
alter a population should be thoroughly assessed before use.
Nontargeted wild organisms.
In theory, precision drives could limit alterations to targeted populations, but the
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reliability of these methods in preventing spread to non-target or related populations will
require assessment. To what extent and over what period of time might cross-breeding or
lateral gene transfer allow a drive to move beyond target populations? Might it subsequently
evolve to regain drive capabilities in populations not originally targeted? There may also
be unintended ecological side effects. Contained field trials should be performed before
releasing organisms bearing a drive that spreads the trait.
Crops and livestock.
A technology capable of editing mosquito populations to block disease transmission
could also be used to alter populations of agricultural plants or livestock by actors intent
on doing harm. However, doing so surreptitiously would be difficult because many
drive-containing organisms must be released to alter populations within a reasonable time
span. Moreover, drives are unlikely to spread undetected in contract seed production farms
and animal breeding facilities that test for the presence of trans-genes. It would thus be
difficult to use drives to affect food supplies in the United States and other countries that
rely on commercial seed production and artificial insemination. Developing countries that
do not use centralized seed production and artificial insemination could be more vulnerable.
Humans.
Gene drives will be ineffective at altering human populations because of our long
generation times. Furthermore, whole genome sequencing in medical diagnostics could
be used to detect the presence of drives. Drives are thus not a viable method for altering
human populations. Rare individuals might experience an allergic reaction to peptides in
the Cas9 protein if exposed to an affected organism. Thus, toxicological studies should be
conducted to confirm that proposed drive components are safe.
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2.2.4 Toward Risk Management
We recommend the following steps toward integrated management of environmental
and security risks:
i Before any primary drive is released in the field, the efficacy of specific reversal drives
should be evaluated. Research should assess the extent to which the residual presence
of guide RNAs and/or Cas9 after reversal might affect the phenotype or fitness of a
population and the feasibility of reaching individual organisms altered by an initial
drive.
ii Long-term studies should evaluate the effects of gene drive use on genetic diversity
in target populations. Even if genome-level changes can be reversed, any population
reduced in numbers will have reduced genetic diversity and could be more vulnerable
to natural or anthropogenic pressures. Genome-editing applications may similarly have
lasting effects on populations owing to compensatory adaptations or other changes.
iii Investigations of drive function and safety should use multiple levels of molecular
containment to reduce the risk that drives will spread through wild populations during
testing. For example, drives should be designed to cut sequences absent from wild
populations, and drive components should be separated.
iv Initial tests of drives capable of spreading through wild populations should not be
conducted in geographic areas that harbor native populations of target species.
v All drives that might spread through wild populations should be constructed and tested
in tandem with corresponding immunization and reversal drives. These precautions
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would allow accidental releases to be partially counteracted.
vi A network of multipurpose mesocosms and microcosms should be developed for testing
gene drives and other advanced biotechnologies in contained settings.
vii The presence and prevalence of drives should be monitored by targeted amplification
or metagenomic sequencing of environmental samples.
viii Because effects will mainly depend on the species and genomic change rather than the
drive mechanism, candidate gene drives should be evaluated on a case-by-case basis.
ix To assess potentially harmful uses of drives, multidisciplinary teams of experts should
be challenged to develop scenarios on deliberate misuse.
x Integrated benefit-risk assessments informed by the actions recommended above should
be conducted to determine whether and how to proceed with proposed gene drive
applications. Such assessments should be conducted with sensitivity to variations in
uncertainty across cases and to reductions in uncertainty over time.
2.2.5 Regulatory Gaps
The prospective development of drives highlights the need for regulatory reform.
Currently, U.S. regulations would treat drives as veterinary medicines or toxins. U.S.
policies and international security regimes rely on a listed-agent-and-toxin approach.
Neither addresses challenges posed by gene drives and other advanced biotechnologies.
U.S. environmental regulations
Responsibility for regulating animal applications of drives in the United States rests
with the Food and Drug Administration (FDA). An FDA guidance issued in 2009 states that
28
genetically engineered DNA constructs intended to affect the structure and function of an
animal, regardless of their use, meet the criteria for veterinary medicines and are regulated
as such. Developers are required to demonstrate that such constructs are safe for the animal.
Approval of new veterinary medicines is to be based on the traditional FDA criterion ‘‘that
it is safe and effective for its intended use"6. It is unclear whether these requirements
can be reconciled with projected uses of drives, including suppression of invasive species.
Nor is it clear how this guidance would apply to insects. The application of existing
U.S. Department of Agriculture (FDA) and U.S. Environmental Protection Agency (EPA)
regulations governing genetically modified organisms to gene drives is also ambiguous,
with jurisdictional overlaps across the Federal Insecticide, Fungicide, and Rodenticide
Act, the Toxic Substances Control Act, and theAnimal and Plant Health Inspection Service8.
International environmental conventions
Existing international conventions cover international movements of gene drives,
but do not define standards for assessing effects, estimating damages, or mitigating
harms. International movements of living modified organisms are treated under the
2003 Cartagena Protocol on Biosafety, ratified by 167 nations not including the United
States and Canada. Article 17 of the Protocol obligates parties to notify an International
Biosafety Clearinghouse and affected nations of releases that may lead to movement of
living modified organisms with adverse effects on biological diversity or human health.
Other provisions empower nations to use border measures to limit international movements,
but these measures are not likely to control diffusion of drives. The 2010 Nagoya-Kuala
Lumpur Supplementary Protocol calls on Parties to adopt a process to define rules
governing liability and redress for damage from international movements. Neither the
process nor rules have been defined4.
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U.S. security policies
The draft U.S. Government Policy on Dual Use Research of Concern (DURC) combines
a broad definition of concerns with a narrow definition of scope of oversight, the latter
focusing on experiments of concern on listed pathogens and toxins9. The listed-agent-toxins
approach is also used in the U.S. Select Agent Rule, USDA Select Agents/Toxins, and
Commerce Department export control regulations. Drives do not fall within the scope of
required oversight of DURC and other listed-agent-toxin-based policies.
International security conventions
The UN Biological Weapons Convention defines areas of concern in broad terms
with the intention of providing latitude to adapt to evolving technologies and threats.
Article 1 bans development, production, or stockpiling of all biological agents or toxins
that have no justification for prophylactic, protective, and other peaceful purposes and
weapons, equipment or means of delivery designed to use such agents or toxins for hostile
purposes1,2. However, national implementation measures defining operational oversight
and Australia Group Guidelines governing exports rely on narrow lists of organisms,
toxins, and associated experiments7. Gene drives and most other advanced applications of
genomic engineering do not use proscribed agents or create regulated toxins and hence fall
beyond the scope of operational regulations and agreements.
Filling the regulatory gaps
We recommend adopting a function-based approach that defines risk in terms of the
ability to influence any key biological component the loss of which would be sufficient to
cause harm to humans or other species of interest. The agents and targets of concern with
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a functional approach could include DNA, RNA, proteins, metabolites, and any packages
thereof. Thus, suppression drives would be covered because they would cause loss of
reproductive capability in an animal population, whereas an experimental reversal drive
that could only spread through engineered laboratory populations could be freely developed.
Steps taken tomitigate environmental concernswill address security concerns and vice versa.
Regulatory authority for each proposed RNA-guided gene drive should be granted to the
agency with the expertise to evaluate the application in question. All relevant data should
be made publicly available and, ideally, subjected to peer review82.
2.2.6 Conclusions
For emerging technologies that affect the global commons, concepts and applications
should be published in advance of construction, testing, and release. This lead time enables
public discussion of environmental and security concerns, research into areas of uncertainty,
and development and testing of safety features. It allows adaptation of regulations and
conventions in light of emerging information on benefits, risks, and policy gaps. Most
important, lead time will allow for broadly inclusive and well-informed public discussion
to determine if, when, and how gene drives should be used.
2.3 Implications of Bio-Design Automation
As discussed in this chapter, there are some synthetic biology applications that expose
considerable regulatory gaps in both U.S. and international regulatory frameworks and
these applications require additional risk-assessment research. Moving forward, there will
need to be mechanisms for automatically flagging projects and applications with such
concerns. One such solution is to build software tools for automated risk assessment
of sequences and applications. Currently, the only known tool to solve this problem is
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Synthetic Genomics’ Archetype tool. However, since it is a proprietary software, the way
in which it screens sequences is not clearly documented and there is no open-source tool
for evaluating sequences in an open community.
Since the bio-design automation field aims to accelerate the scale and pace of synthetic
biology, it important to begin developing tools for addressing biosecurity concerns. It
would also be useful to include metrics for risk assessment in future design tools, so that
designs that create risk are flagged for additional evaluation.
At its current scale and pace of development, considerable regulatory gaps are already
exposed by current synthetic biology applications and the number of projects with such
concerns will only increase as the pace of technological advance accelerates. Fortunately,
this also poses great potential for software developers to create tools to flag and document
risky designs or designs that raise biosecurity concerns. In coming years it will become
more and more important for synthetic biologists to ask themselves which projects they are
pursuing and why before the path of research is defined, as their design power increases
from bio-design automation tools.
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3 Design Workflow Overview
Once a synthetic biologist has determined which application to develop and given due
consideration to the biosecurity and risk assessment aspects, they must form a plan for
developing the technology. In synthetic biology, this requires a full workflow that includes
creating genetic designs, physically assembling them, testing them, and using the outcomes
to refine designs, if necessary. This thesis is focused on building a tool to automate
decisions in each one of these areas for a workflow tailored to building transcriptional
regulatory networks in E. coli. To accomplish this task, we created a tool called Phoenix.
Phoenix combines seven existing software tools and introduces more than four additional
sub-problem definitions and solutions. A majority of these tools are not presented directly
to a user, but are used extensively on the back end.
Phoenix receives an input design specification and parts library and produces a design
hierarchy for the input design specification. It then returns a set of experimental instructions
for the lowest lever of the design hierarchy for the user to implement. After the user
completes the experiment, they return the collected data to Phoenix as per the experimental
instructions and, as additional phases of building and testing are necessary, Phoenix returns
new sets of building and testing instructions to the user for each level in the design hierarchy.
In instances where the acquired experimental results do not match the simulated predictions,
Phoenix instructs additional building and testing instructions to attempt to isolate design
failures.
This process starts with uploading of all DNA sequences features and plasmids into
a sequence editor tool (Benchling) and exporting annotated sequences into a multi-part
Genbank file. These file are then uploaded into Phoenix and saved into the user’s Clotho
database (Step 0). Phoenix is then idle until it receives a set of design specifications
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Figure 3: Phoenix tool software architecture
from the user (Step 1) in the form of a performance-constrained signal temporal logic
equation (STL) (‘function’ and ‘performance’ specifications) and a constraint set used
to produce abstract genetic regulatory networks (AGRNs) using miniEugene (‘structural’
specification). These specifications are verified for validity and then decomposed using
structure- and function-based grammars within Phoenix (Step 2).
These decomposed genetic structures are then supplemented with temporary testing
parts and the first round of optimized part assignment is performed to determine the se-
quence-assigned constructs for the first testing phase (Step 3). These target parts and the
parts library are then exported into Raven14 to produce an optimized DNA assembly plan
(Step 4). At this point, the user is returned a file with instructions for DNA assembly,
oligos needed for assembly, and a ‘key file’ that represents the testing conditions required
for subsequent data analysis (Step 5) after building is complete.
The user then executes the building and testing instructions and returns cytometry data
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and new multi-part GenBank files for the new plasmids back into Clotho via the sequence
editor and the annotated key file (Step 6). Raw cytometry data is processed by a data analysis
script using the Bioconductor library in R (Step 7) and the processed data is then mapped
to an SBML file, representative of the core Phoenix mechanistic model. An algorithm for
parameter estimation is applied from the COPASI toolbox to determine rate constants for
each construct from the input data (Step 8).
At this point, all parameters for the current stage of the design hierarchy are known and
can be used to simulate compositional behavior with COPASI (Step 9). Next, each sim-
ulation is model-checked with the decomposed functional specification for each construct
and those constructs which do not satisfy the specified performance are filtered out, and
those that satisfy the decomposed functional specification are rank-ordered for robustness
(Step 10). Then, the constructs that are predicted to most robustly meet the decomposed
functional specification are mapped back to parts and another round of part assignment
optimization (Step 11) is performed. Lastly, the results of both the simulated and observed
behavior can be viewed with electronic datasheets using Owl13 (Step 12).
In instances where there are mismatches between the simulated compositional behavior
and the data acquired upon building and testing, Phoenix uses grammars that define common
failure modes of transcriptional regulatory networks to instruct the building and testing of
additional intermediate networks to probe changes in the rate constants with respect to the
rate constants deduced from the first phase of testing.Steps 4-12 are repeated iteratively up
the design hierarchy determined by the Phoenix grammars (Step 2), but the user only ever
views building end testing instructions (Step 5), a graphical map of the design hierarchy
(Step 2) and results in the user interface (Step 12).
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4 Genetic Regulatory Network Design Specification
The entry point to any design-build-test-learn cycle is the design specification. This rep-
resents the formal description of the desired outcome (i.e. ‘target’) of a project. In synthetic
biology projects, design specifications are typically defined informally as ‘design objectives’
that can range from a target yield of a small molecule produced by cells’ metabolism to a
target level of expression of a gene of interest. Design specifications can also be formal
mathematical descriptions of functional behavior. Other engineering fields rely on formal
specification tools and methods because they are well-defined, which allows for quantitative
reproducibility and can be analyzed to create more complex function. Furthermore, formal
specifications provide a strong foundation for compositional designs that rely on the defined
function of their components.
In synthetic biology, formal design specification has not been explored deeply, but many
formal specifications come in the form of boolean truth table. This is a powerful and simple
abstraction borrowed from electrical engineering that a digital output (1 or 0) for an arbitrary
number of digital inputs (also 1 or 0). Recent work has demonstrated sophisticated boolean
logic function for a variety of genetic network types. Boolean logic has been demonstrated
for transcriptional regulatory networks97, recombinase-based networks91, and RNA-based
networks65 and still currently serves as the inspiration for many synthetic biology projects.
While this abstraction has garnered a lot of excitement due to its importance in other
engineering fields and has recently been widely adopted in parts of the synthetic biology
community, there has yet to be a clear application of genetic logic used to solve a real-world
problem. From a technical perspective, boolean specifications are not time-dependent and
generally are not performance-constrained. For example, this type of specification cannot
be easily used to specify a genetic toggle switch47 or a genetic oscillator40,95. These
36
specifications also do not have easy ways for attaching quantitative performance metrics.
An ideal specification for synthetic biology applications would define the desired func-
tion and performance for a wide variety of synthetic genetic networks. Given the breadth
of platforms used in synthetic biology, it would also be useful and necessary to supply
a structure-based specification, or AGRN. Also considering this breadth of platforms, it
does not seem reasonable that a function alone can be used to determine what performance
should be required of any target network or which type of network platform would be best
for satisfying an particular function. For these reasons, in Phoenix, a user must enter a
specification that individually defines the desired structure, function and performance of
a target network. It would be desirable to create a design ‘language’ that can be used a
specification tools to create and validate designs.
4.1 Grammars for Design Decomposition
In computer science, an important abstraction for validating expressions a language is
grammars. Formal grammars are defined by four components: 1. Terminal symbols which
serve as the elemental building blocks; 2. A start symbol to represent a complete statement;
3. Non-terminal symbols which serve as intermediate symbols between terminals and
the start; and 4. Production rules for defining how terminal symbols can be combined to
produce non-terminals and ultimately a start. To give a non-technical example, consider
a sentence in English. A sentence would be the start symbol and the words would be the
terminals. Non-terminals would include clauses, phrases and participles which are made
from terminals and used to build a full sentence.
Grammars can be useful for generating sets of complete start symbols given a library
of terminals, but can also be used to decompose a start symbol into its terminals. This can
be useful for breaking very large expressions into it’s elements. In Phoenix, we apply this
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abstraction to structural genetic design specifications to decompose these specifications into
abstract design trees.
4.1.1 Signal Temporal Logic
In systems engineering, there is a set of formal methods used for time-dependent
specifications called temporal logics. These logics are used for a variety of applications,
including robotics, and also include the set of all boolean expressions. One particular logic
in this family of specification languages, signal temporal logic STL, can specify a signal
over time with performance constraints. Me and my collaborators selected this language as
the form of function and performance specification in Phoenix.
Figure 4: Specification of a ‘NOT gate’. The English language specification and STL specification
(left). An example of a NOT gate structure and illustration of the temporal function (right).
This language has its own grammar to validate STL expressions independent of their
applications, but no current mechanism by which to decompose an STL function into its
sub-functions. Since this math does not yet exist, in Phoenix, we leverage another STL
variant, parameterized STL (PSTL) to compose to compose large specifications consisting
of the functional terminals: ‘NOT gate’, ‘toggle switch’ and ‘oscillator’.
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4.1.2 Abstract Genetic Regulatory Network Specification
Each genetic platform has different structural genetic elements. Transcriptional GRNs
in textitE. coli can be defined as compositions of promoters, ribosome binding sites (RBSs),
regulator coding sequences, terminators and vectorswith origins of replication and antibiotic
resistance. From these five elements, an infinite number of AGRNs can be created, but only
a subset of those AGRNs contain complete sets of transcriptional units arranged to express
all contained regulatory coding sequences.
Figure 5: Structural specification inPhoenix. An exampleminiEugenefilewith structural constraints
(left). Three valid AGRNs from this structural specification (right)
Phoenix, has a grammar for determining if a candidate AGRN contains complete sets
of transcriptional units, considering both the forward and reverse strands. Phoenix comes
pre-loaded with files that can be input into an AGRN-generation tool, miniEugene, and
define the set of all valid AGRNs for a transcriptional ‘NOT gate’, ‘toggle switch’ and
‘oscillator’. These AGRN outputs are considered the starts of the structural grammar and
map to the terminals of the STL grammar.
In Phoenix, we use this grammar to decompose genetic structures into abstract design
trees. The foundation of these grammars are the biochemical interactions involved in genetic
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Figure 6: (a) Grammar in Phoenix going from a functional non-terminal to a structural terminal
(left). (b) A symbolic representation of an example design decomposition.
transcriptional regulation and the types of structural genetic elements that are required
for transcription, translation, and transcriptional regulation. Our grammars recognize
four types of genetic elements: transcriptional promoters, ribosome binding sites (RBSs),
coding sequences for transcription factors (CDSs) and transcriptional terminators. The
use of specialized RBSs, called BCDs71 is assumed throughout to shield the impact of
adjacent CDSs on expression. The grammar is used to identify sets of these genetic
elements on both strands and determine if candidate sets of these elements exclusively
produce 1 or more transcription factors (i.e. no partial production of bio-molecules is
allowed). Once it is determined that a set of genetic elements is valid, the grammar
identifies subsets of these structures that produce single transcriptional regulatory ‘arcs’
and identifies single transcriptional units within those structures. Finally, the grammar
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identifies sets of components within a transcriptional unit that enable the expression of
a transcription factor (called EXPRESSORs) and the coding sequences that get expressed
as proteins (called EXPRESSEEs). The decomposition is done this way such that the
leaves of the tree (EXPRESSORs and EXPRESSEEs) represent sets of elements that are
responsible for independent measureable parameters in the enzymatic models for these
structures. Specifically, EXPRESSORs are the ordered sets of parts that contribute to
the expression parameter of a transcriptional unit and EXPRESSEEs are the elements are
ultimately translated into proteins in the cell which have a degradation, regulation parameter,
and sometimes a small molecule interaction parameter.
4.2 Mechanistic Modeling of Genetic Regulation
Figure 7: As opposed to performing measurements to determine rate constants specific to single
interactions for expression (a), Phoenix ‘black-boxes’ these expression interactions into a single
composite constant for expression.
The decomposition of transcriptional GRNs is informed by the modeling paradigm used
to understand the mechanistic interactions driving these networks. In Phoenix, a modeling
paradigm from other current work is adopted that black-boxes protein expression to one
rate constant that represents all reactions required to produce a protein. This includes
transcription initiation, elongation, and termination; translation initiation and elongation;
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mRNA degradation; and DNA replication. This composite expression constant is the only
constant measured for EXPRESSORs.
Figure 8: (a) The core models in Phoenix consider both expression and degradation kinetics (b)
Three example regulatory networks (c) Mass action kinetic models for the three example networks
with the Phoenix modeling approach.
More individual reactions are measured for EXPRESSEEs: protein degradation; protein
expression of a promoter as a function of the quantity of its correspondingEXPRESSEE; and
the degree with which a small molecule inducer in the environment impacts this relationship.
Each one of these reactions are measured individually in the Phoenix environment with the
addition of standard testing components.
4.3 Insertion of Testing Components
Specifications decomposed with the Phoenix grammars result in a tree of genetic com-
ponents that are still not visible to any form of measurement. In the Phoenix tool, we
use single-cell fluorescence as the mechanism of functional measurement. Since this tech-
nology has single-cell resolution and can measure a large number of fluorescent reporters
simultaneously, it is an ideal choice to measure the signal produced by genetic regulatory
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networks.
When using the production of fluorescent reporters as probes for the regulatory function,
there arises a question of how to position this probe in the construct beingmeasured. There is
a variety of options for this probe including using a separate transcriptional unit driven by the
same promoter, bi-cistronic transcriptional unit designs, and fluorescent-fused regulators.
In Phoenix, fluorescence-fused regulators are the method of choice since they are the most
direct measurement of a regulator’s expression and share the same degradation properties
in a fused complex.
Figure 9: (a) After design decomposition, testing components (blue) must be added to the de-
composed design components (black). (b) Once the position of fluorescence-fused regulators is
determined, a fluorescent protein must be selected from a set of available fluorescent proteins with
respect to a particular measurement machine.
Phoenix applies this probing strategy throughout, but in cases where multiple fluores-
cence-fused regulators appear in one construct (which is true of all functional terminals and
thus also larger designs), it must be determined which fluorescent protein to use in each fu-
sion. Since there currently exist no algorithms for selecting sets of fluorescent proteins, we
developed an algorithm for selecting fluorescent proteins based upon minimizing spectral
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overlap across fluorescence emission spectra.
Once the fluorescent proteins are selected for the construct at the functional root, these
selections are propagated down the design tree. For some constructs, all of the elements
necessary for expressing a fluorescent protein signal for measurement are not yet present.
Phoenix solves this problem by assigning default testing elements with pre-measured prop-
erties where necessary.
In the final set of operations for adding testing components, Phoenix instructs the cre-
ation of plasmids to be used as controls formeasuring the properties ofEXPRESSEEs. These
plasmids have two transcriptional units - one controlled by the EXPRESSEE’s promoter to
express a fluorescent protein and one to express a gene for the environmentally-inducible
control of the promoter driving the expression of the EXPRESSEE. This allows for control-
lable measurements of how an EXPRESSEE regulates its corresponding promoter.
4.4 Part Assignment
Upon the creation of the abstract design tree, the sub-structure of genetic elements at
each node is determined, but the DNA sequences of each element are not sequence-assigned.
The process of filling in this AGRN to create a sequence-complete GRN is called part
assignment.
There are some existing tools for part assignment102, but they are restricted to log-
ic-based abstractions and do not make considerations for AGRN arrangements, or default
testing sequences. Upon initial design decomposition and testing element addition, a partial
sequence assignment is performed for promoter-regulator pairs to assure that only orthog-
onal pairs of regulators and promoters are used in each functional terminal. In this initial
partial assignment step, RBSs, terminators and vectors are left unassigned. The user is
instructed to multiplex all of their eligible RBSs, terminators, and vectors in the terminal
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testing constructs to maximize functional diversity. This is done because the functional di-
versity represents the ‘performance library’ for the target design and a larger library implies
more possible combinatorial compositional designs.
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5 Interactive DNA Assembly
5.1 DNA Assembly Background
Once a full set of GRNs has been assigned, it must be determined how to clone the
designs efficiently. Cloning technology has increased in scale and complexity since it
was invented 40 years ago. In the past decade, a number of DNA assembly methods
have emerged42,48,62,81,89,99 that include restriction-ligationbased and homologous recom-
binationbased cloning systems, and many follow the design model of assembling genetic
’constructs’ from genetic ’parts’41. While the precise definitions of these terms have been
debated15, the consensus is that parts are DNA segments and constructs are ordered sets of
these parts. Given this designmodel, two fundamental questions arise: First, how should we
identify and select parts to create the desired functional genetic constructs? Second, once
these constructs have been selected, how do we physically assemble them? The following
work formalizes this second question and provides algorithms that address experimental
realities to improve the speed, modularity and experimental efficiency of this process for
state-of-the-art DNA cloning techniques.
Cloning-based assembly approaches can be broadly classified into binary assembly
techniques, where twoDNAparts are assembled in one cloning step, andmulti-way (one-pot)
assembly techniques, where two or more parts are assembled in one step. Generally
speaking, multi-way assembly methods are faster because they can minimize cloning steps
and can be exploited to leave no assembly artifacts in a completed construct, while binary
assembly methods typically require more cloning steps, but in some cases utilize specific
cloning sites to allow a simpler standardization of part composition and modularity.
Previous work25,37 detailed hierarchical assembly algorithms for binary assembly90 but
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Figure 10: The graphic symbols are composed using Pigeon23 (http://www.pigeoncad.org/) from
SBOL45 (http://www.sbolstandard.org/) visual images to denote part types. (a) The repressilator.
(b) Starting library consists only of template DNA. (c) A plan for assembling the repressilator given
b requires 13 PCRs, 4 steps and 2 stages. Two steps fail (steps 2 and 3; red boxes), one step succeeds
(step 1; green box) and the dependent step in the second stage cannot be attempted (orange box). (d)
The updated library contains basic parts and intermediate parts with specific overhangs from c. (e)
An optimized plan, in which all steps succeed (green boxes), is generated with no PCRs, three steps
and two stages.
lacked formulation to address more modern multi-way assembly techniques. There are few
automated tools to exploit the high degrees ofmodularity and reuse formulti-way techniques,
and no tools for producing complete assembly plans. Some approaches52 detail the process
of automatically selecting oligonucleotides and analyze trade-offs between cloning and gene
synthesis for multi-way assembly; however, they do not optimize cloning steps and stages.
This section describes a method for performing optimizations on intermediate cloning
step selection and part junction selection for any number of target constructs while con-
sidering a library of existing parts for reuse. My collaborators and I show that for sets of
thousands of variants of multiple types of contemporary genetic constructs and a large set
of constructs from the literature26,27,44,64,69,91,96,97, our program outperforms unoptimized
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solutions (P(z) < 0.001), andwe then experimentally verify a small subset of these optimized
solutions by reconstructing ‘genetic counter’ and ‘repressilator’ constructs. This work also
details, to our knowledge, the first automated cloning workflow in which experimental
outcomes may be directly fed back into the software to recalculate an alternative assembly
plan.
The algorithms presented are housed in an online web application called Raven that
produces full assembly plans in human- and computer-readable instructions and graphical
Synthetic Biology Open Language (SBOL)-compatible images for each of the supported
assembly methods42,48,62,81,90,99.
In this work, I break the problem of assembling a set of DNA constructs with a selected
cloning technique into three main subproblems. First, the algorithms determine an opti-
mized hierarchical cloning plan for assembling a set of constructs. For this part, Raven uses
dynamic programming to reduce the computational time it takes to solve the large problem
of selecting intermediate cloning steps for a set of target constructs into smaller sub-prob-
lems. Because the heuristic scores for assembling a specific intermediate are assumed to
remain constant regardless of previous or future cloning steps, once an optimized heuristic
solution for an intermediate is found, the solution is reused if the candidate intermediate
step is encountered again. For constructs that share parts internally or share parts with other
target constructs, sharing of assembly intermediates can reduce the total step count consid-
erably, and, if many steps can be done in parallel, the number of cloning stages can also
be minimized. The cloning step solution comprising all the stages and steps necessary to
build the target constructs under consideration constitutes a hierarchical ‘assembly graph’.
Second, the algorithms determine an optimized set of part junctions (hereafter referred
to as ‘overhangs’) required to perform the selected cloning steps. Overhang assignment,
which aims to minimize overhang generation cost (hereafter ‘PCR steps’), is determined
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in three steps. First, the requirements for overhang uniqueness based on the selected
assembly method are determined (for example, all parts must have unique pairs in each
individual cloning step). Second, for modular overhang assignment, overhang pair sharing
is maximized for all cloning steps where sharing can eliminate extra steps and the total
number of unique overhang sequences is minimized. The second step is skipped for some
assembly methods because it is assumed that all overhangs are either the same or all are
unique. Third, after all overhang pairs have been determined, the existing parts library
is used to map abstract overhangs to DNA sequences, maximizing library reuse with a
constrained Cartesian product (Figure 15).
Third, based on the cloning steps and their overhangs, oligonucleotides for PCR are
automatically designed (Figure 10a-c). For all PCR steps, primers are designed on the
basis of part, overhang sequence, direction (forward or reverse strand) and assembly method.
The primer designs are optimized for length and melting temperature, but other complex
optimizations are not considered. For more sophisticated primer designs, we provide
outputs compatible with existing state-of-the-art primer design software52. The summary
of all cloning steps, PCR steps and oligonucleotide designs constitutes a complete ‘assembly
plan’.
Following Raven’s assembly instructions, a user might encounter some assembly steps
that fail. The user can then mark each step in the plan as successful, failed or not attempted
(as a result of step failures in an earlier stage) (Figure 10c) to recalculate an alternative
assembly plan. The parts from the successful steps are added to the library and failed steps
are forbidden from appearing in a new plan (Figure 10d,e). The interactive refinement of
an assembly plan is meant to be independent of specific protocols and reaction conditions
and can complement troubleshooting specific reactions in a preliminary plan. This process
continues iteratively until all target parts are assembled. As this algorithm relies on heuristics
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in many locations, we cannot make any claims that it is optimal. However, we can prove
that the solutions are correct in linear time as a function of the number of intermediates.
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5.2 In silico assembly of thousands of constructs
To determine the quality of Raven’s assembly plans, me and my colleagues compared
our solutions against unoptimized solutions for each data set by randomly sampling the
assembly plan space for each set of constructs under consideration. For both unoptimized
solutions and Raven solutions, we assumed no preexisting library of parts except template
DNA and constrained our assembly calculations such that a maximum of six parts could
be assembled per reaction for one-pot assemblies, as reactions with more parts show low
efficiency.
First I considered several published sets of complex genetic constructs covering a variety
of sizes, types and architectures26,27,44,64,69,91,96,97. For each of these sets, we determined
optimized and unoptimized solutions for BioBricks (BioBricks Foundation request for
comments (BBF RFC) 10), MoClo (BBF RFC 94) and Gibson assembly methods.
Assembly solutions were scored in terms of cloning stages, cloning steps and PCR steps,
and the Raven solutions are compared to average unoptimized solutions (Table 2) and
the best unoptimized solutions (Table 3). Raven’s solutions were significantly better than
unoptimized solutions for assembly stages (P(z) < 0.01) for all three assembly methods for
nearly all construct sets. Raven’s MoClo solutions were significantly better for both cloning
steps and PCR steps (P(z) < 0.01). Raven’s solutions had significantly fewer cloning step
solutions for Gibson (P(z) < 0.01) for all construct sets, and in only one BioBricks solution
did the unoptimized plans result in fewer steps. However, as Raven’s strongest scoring
heuristic is cloning stages, when selecting the best assembly plan, Raven allows additional
steps in favor of fewer stages. Similarly, the summary of all sets has a better cloning-step
solution for BioBricks because of the inclusion of the aforementioned set, which contains
by far the greatest number of constructs of the considered construct sets. For BioBricks and
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Gibson cloning, the number of PCRs is not optimized, so all Raven answers are equivalent
to those of the unoptimized solution.
Next, to demonstrate the power of Raven solutions on an even larger scale, I used
Eugene73 to generate a set of 1,000 or more variant constructs for five separate types of
constructs: DNA invertase cascade (DIC) counters, toggle switches, repressilators, tran-
scriptional NOR gates and invertase NOR gates (Figure 11a). Because it is common for
large constructs to need tuning to achieve function, these sets contain variants to represent
a spectrum of possible function and provide many opportunities to share intermediates.
To determine one unoptimized solution for each of these sets, a script randomly selected
500 constructs and calculated an unoptimized, one-pot hierarchical assembly graph. We
repeated this experiment 1,000 times for each of the five designs to get a distribution for
each type of design and found that Raven’s algorithms were able to select assembly graphs
that require significantly fewer cloning steps than the average unoptimized graphs for all
five designs (P(z) < 0.001) (Figure 11b). Because these data sets were made from com-
binatorial part substitutions, there exist many opportunities to share cloning intermediates
and assembly vectors using modular overhangs. My team observed that our modular over-
hang assignment solutions required significantly fewer PCRs than unoptimized solutions
for overhang assignment for each of the five design types (P(z) < 0.001) (Figure 11c).
Finally, I determined how Raven’s solutions performed as a function of the number of
constructs under consideration. We repeated the in silico experiments for the five design
types for variable numbers of constructs. I found that Raven’s solutions significantly outper-
formed the unoptimized solution spaces for both cloning steps and PCR steps (Figure 11d)
at a small scale of 5 constructs (P(z) < 0.001) as well as at a larger scale of 500 constructs
(P(z) < 0.001). As the number of constructs under consideration increases exponentially,
Raven’s solutions for both hierarchical assembly and overhang assignment also improve
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Figure 11: (a) SBOL visual representations of the DIC counter, invertase NOR gate, repressilator,
toggle switch and transcriptional NOR gate constructs, indicating the number of parts we sampled
at each position and the total possible construct variants after application of Eugene rules. (b)
Cloning steps required for MoClo assembly of a 500-construct subset of each set of 1,000 or more
constructs from a. Asterisks represent the Raven solution; other points represent unoptimized
cloning step solutions. (c) PCR steps required for MoClo assembly given the cloning step solution
in b. Asterisks represent the Raven solution; other points represent random PCR step solutions. (d)
The fold improvement of Raven’s solution compared to unoptimized solutions in b,c as a function
of construct quantity. Raven’s solutions improve as the number of constructs per assembly plan
increases. PCR steps (dashed) and cloning steps (solid) are shown separately.
exponentially compared to unoptimized solutions (Figure 11d).
5.3 Interactive Assembly of Genetic Constructs
To highlight Raven’s ability to utilize an existing library of constructs, I used it to
calculate an assembly plan for six repressilator40 constructs using an existing library with
an existing overhang schema. The constructs were designed based on previously published
schema using the CIDAR (http://www.cidarlab.org/) MoClo library as a resource. Design
constraints allowed only up to four parts per cloning step, as opposed to six. The assembly
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plan for these six constructs required 17 assembly steps, 2 assembly stages, 0 PCR reactions
and 23 shared parts, and we successfully constructed two constructs without modification
to this plan (Figure 25).
I then selected a subset of the constructs from Friedland et al.44 (representing some of
the largest and most complex constructs in the sets) and constructed them using Raven. I
used a MoClo assembly plan (BBF RFC 94) for the DIC counter constructs, assuming a
library of only template DNA and cloning vectors. The Raven-designed oligonucleotides
from the assembly plan were used to amplify parts using the original constructs as template
(Figure 17), overhang sites were chosen from a preselected set of 4-bp modular scars and it
was assumed that all cloning steps would have equivalent cloning efficiency. The assembly
plan for all four constructs required 29 steps, 3 stages and 34 PCR steps (Figure 12a, Fig-
ure 19). I implemented this preliminary assembly plan as specified by the human-readable
instructions that Raven generated, using standard reaction conditions (Figure 12a).
This initial plan was not successful. However, Raven has four primary mechanisms
for interactively modifying assembly plans to circumvent unsuccessful cloning steps. First,
Raven can detect undesirable restriction sites that can be removed with PCR. Second,
intermediate clones flagged for expressing undesirable genes (such as the flpe recombinase)
or other traits (Figure 12b) can be biased for or against appearing in an assembly plan
(Figure 23). Third, default cloning vectors assigned to each assembly stage based on each
assembly method may be substituted. Finally, cloning efficiency as a function of number
of parts assembled per cloning reaction may be modified from default equivalent-efficiency
values (Figure 24).
In cases where users have already started a large assembly but get stuck on unforeseen
challenges, they can use the Raven redesign feature (Figure 12c) to calculate a new plan.
When using this feature, Raven automatically adds the successful parts into the library and
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Figure 12: Interactive Assembly (a) An initial assembly plan in the Raven UI. (b) A SpeI restriction
analysis for Level 1 cloning intermediates (1-6) with expected bands at 0.5kb, 1.7kb & 0.2kb, 2.1kb,
1.7kb, 1.5kb and 2kb, and 3.4kb, respectively, with a 2.1kb vector band. Incorrect bands seen for
lanes 2 & 5. (c) In the Raven UI redesign tab, failure of these intermediates and success of all other
intermediates is reported and a new plan is generated. (d) A PstI restriction analysis for the complete
genetic counter constructs should be 7kb, 4kb & 1.6kb
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forbids failed intermediates from appearing in the alternative solution. When I got stuck on
the first plan for the counters, we used a redesigned solution, which required seven steps, two
stages and two PCR steps (Figure 20). This plan reused the four successful intermediates
from the initial plan and split up the two unsuccessful intermediates into smaller intermedi-
ates. One of these intermediates was also unsuccessful, so a second redesign with the same
cost was implemented that succeeded in the cloning of all intermediates (Figure 21).
This third plan, although successful for creating all intermediates, was not successful for
cloning the final constructs. This was because BBF RFC 94 assumes the use of high-copy
plasmids for all cloning steps. In this case, since it is critical that recombinases are not
expressed, it was problematic to clone the final counter constructs into high-copy plasmids
owing to leaky promoter behavior. To address this, I forced an extra cloning stage by
requiring the construction of larger intermediates and assigned a pBAC for the final cloning
stage (Figure 21).
Using this plan, all cloning intermediates were constructed and used to build the final
constructs successfully (Figure 12d). Several of the intermediates incurred mutations as a
result of cloning artifacts, but these were located at internal part junctions and the flanking
junctions needed for future steps remained unaltered. Therefore, Raven cannot guarantee
the production of an exact target sequence; in vivo recombination events are difficult to
predict and outside the scope of the assembly plan. Moreover, as long as the necessary
restriction sites and part junctions remain intact, the Raven plan remains valid.
5.4 Multiplex Assembly of Genetic Variants
The current paradigm in the cloning community is to define the complete sequence of
target constructs before assembly, and set up reactions with only one part in each cloning
position. However, in instances where function diversity of genetic constructs is desired, it
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can be advantageous to perform cloning reactions where instead of putting single defined
sequences in each position of a target clone, a library of variants is used. This style of
cloning is called multiplexing cloning and can be used to create DNA construct variants.
In theory, if equimolar concentrations of all variants in a multiplex cloning reaction
are present, one should expect there to be equal representation of variants among the
screened clones. To confirm this for our cloning reactions, we performed experiments for a
transcriptional expression cassette, where we multiplexed functionally diverse variants for
the promoter, RBS, and terminator positions for up to 8 different variants. We then screened
the number of clones necessary to theoretically pick at least one of each variant assuming
an equal population. We found there to be no detectable bias for any particular sequence
among this set.
Figure 13: (a) The number of sequences observed in sequence screening as a function of the number
of parts multiplexed. In all cases, the theoretical number of colonies needed to encounter at least
one of each sequence was screened. (b) Functional diversity value as a function of the number of
parts multiplexed for the promoter, RBS, and terminator position.
Since we multiplex primarily to obtain diverse functional outcomes, it needed to be
determined if the expression profiles across clones produced diverse expression profiles.
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To determine how functional richness was affected by the number of parts multiplexed, we
measured the expression profile of the variants from each multiplex reaction to measure the
functional richness70. We found that generally as the number of parts multiplexed increased,
the functional richness increased.
5.5 Complexity Analysis
The following complexity analysis shows that the algorithms me and my colleagues
developed for partitioning a goal part into intermediates and assigning overhangs to each
parts is both efficient and scalable (Figure 14).
5.5.1 Multi Goal Part Algorithm
This section describes the run time of the multi-goal-part algorithm. Here, I describe
the worst-case computational scenario for producing an assembly graph. We make no
assumptions about biologically informed compositional rules for genetic constructs, which
could reduce the computational cost of calculating an assembly graph - compositional rules
can be captured using required, recommended, discouraged, and forbidden parts, the use
of which is described in our online documentation at ravencad.org. The multi goal part
algorithm is an extension of the algorithm presented by Densmore et al.37 and uses a similar
dynamic programming scheme to reduce complexity. The worst case for run time is when
there are no parts in the library.
Let there be n goal parts in an assembly with each goal part consisting of an average
of m basic parts. The algorithm begins by making a call to the determineSlack() helper
routine, which calls createAsmGraph_sgp() once for each goal part to determine the size of
the largest graph, the slack.
The first step in createAsmGraph_sgp() is to determine how to partition a part. Suppos-
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ing that a number of parts can be assembled in each reaction, then for a goal part of size m,
is assembled from ceil (ma ) number of intermediates.
If the number of intermediates required to assemble a larger intermediate of size b
exceeds a+1, then therewould be atmost, b choose aways to partition the larger intermediate
into smaller intermediates. Exploring the full combinatorial space of the partitions exceeds
exponential in complexity. Using a least squares approach encapsulated in the getPartitions()
helper method, finding the appropriate partitions for any goal part or intermediate can be
done in constant time assuming a reasonable number of forbidden parts, that is the number
of forbidden parts is less than the Bell number for a set of size m.
Each of the smaller intermediates in turn, would need to be assembled ceil (ma ) interme-
diates in turn. And so createAsmGraph_sgp() would need to make log(m) recursive calls
to createAsmGraph_sgp() to create an increasingly smaller subgraph. The cost for these
recursive calls can be written in the form T (n) = a T (ma ) + c, where c is the constant cost
of finding the partitions and combining several subgraphs, both of which are effectively
constant time operations. Assuming According to Master’s Theorem, these recursive calls
are O(m) in complexity.
And so in total, it costs on the order of nm operations to determine slack. Next, the
multi goal part algorithm makes n calls to createAsmGraph_sgp(), incurring yet another
nm operations. So overall, the multi goal part algorithm is O(mn) in complexity.
5.5.2 Overhang Assignment Algorithm
This section presents the run time analysis for MoClo overhang assignment. The
algorithm for overhang assignment uses a 3 pass, dynamic programming approach. In the
first pass, metadata is added to each node to enforce the MoClo overhang rules -parent
and child nodes, and adjacent nodes (the children of each node are ordered) have the same
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overhang. The second step minimizes the number of overhangs used and the number of
vectors used. The final step maps overhangs assigned in the second step to overhangs that
exist in the library.
In first step of overhang assignment, a recursive helper method is called for each of
the n graphs, which each contain on average m leaf nodes. The helper method visits each
node once, storing metadata and assigning overhangs at each visit, expending n Plogpmi=0 pi
operations where p is the maximum number of parts that can be assembled in a single
assembly step operations. Next for each graph, every node is stored in a hash that stores the
maximum level that the node’s overhang impacts; it takes logpm operations to determine the
maximum level for each node. And so, the first step of our overhang assignment algorithm
costs n  (Plogpmi=0 pi) + n  m  logpm operations.
The second step of the overhang assignment algorithm iterates over all basic part nodes
for each graph twice, once in the forward direction and once in the backwards direction,
costing m operations per graph. In each iteration, an incremented value is assigned to the
left and right overhang of a basic part. Depending on the type of the basic part, the assigned
values are set aside in typeOHHashLeft and typeOHHashRight for assignment to parts of
the same time. To ensure that the restored values give valid assignments, we iterate over the
neighbors of the basic parts, removing any overhangs that would give an invalid assignment,
requiring a total of m operations. So overall, the second step costs a total of nm2 operations.
The final step of the overhang assignmentmaps abstract overhangs to concrete overhangs
that exist in a user’s part library. In the third step of the overhang assignment, abstract
overhangs are first linked to all possible concrete overhangs; this requires iterating over
all basic part nodes in all graphs, as well as all parts in the library, l, adding up to
nm + l operations. Using this information, a constrained Cartesian product is performed
to determine the best assignment of concrete overhangs. In the worst case, no overhang
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pairs are reused and overhangs are used just once, and so there would be 2mn overhangs
that need to be assigned. Given l parts in the library, each abstract overhang would
have roughly lnm concrete options. The Cartesian product produces at most (
l
nm )
nm valid
solutions. The next iteration occurs over each valid solution to score for the best. A final
traversal is then necessary over all graphs to assign the overhangs to the graph. In total,
(nm + l) + ( lnm )
nm + n  (Plogpmi=0 pi) operations are required for the third step.
Summing the cost for all three steps, overhang assignment costs 2n  (Plogpmi=0 pi) + nm 
logpm + 2nm2 + (nm + l) + ( lnm )
nm operations. In most situations, l > m > n, and so the
overhang assignment algorithm has O( lnm )
nm complexity. However, in practice there are
rarely ( lnm )
nm valid solutions in the third step, which would require that each basic part in an
assembly is unique within the assembly. Raven is designed suited for parallelized assembly
plans characteristic of pathway engineering experiments, in which case the number of basic
parts would be the main contributing factor, giving a practical complexity of O(nm2).
5.6 Eugene Rules for 1000+ Construct Sets
A permutation of all possible constructs in Figure 11 for a specific construct type yields
a combinatorially large space. For larger constructs, this space can exceed 1,000 constructs,
but not all constructs are functionally valid. Me and my colleagues wished to constrain
the construct sets to those which are qualitatively valid, so we use Eugene24 to limit this
combinatorial space for each type of construct. Below are the rules for each individual type
of construct.
5.6.1 Counter constructs
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c o n s t r u c t DIC2 ( Promoter , I n v e r t a s e S i t e ,  Promoter , RBS , Gene
, Te rmina to r ,   I n v e r t a s e S i t e , I n v e r t a s e S i t e ,  Promoter ,
RBS , Gene , Te rmina to r ,   I n v e r t a s e S i t e , RBS , Repo r t e r ,
T e rm ina t o r ) ;
Rule r (
ON DIC :
/ / Matching I n v e r t a s e s i t e s
DIC [ 1 ] MATCHES DIC [ 6 ]
AND
DIC [ 7 ] MATCHES DIC [ 12 ]
AND
/ / D i f f e r e n t I n v e r t a s e s i t e s
FRT WITH loxP
AND
CONTAINS rb s1 AND CONTAINS rb s2 AND CONTAINS rb s3
) ;
c o n s t r u c t [ ] l s t = p r o du c t (DIC , s t r i c t , 1000) ;
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5.6.2 Toggle-switch constructs
c o n s t r u c t Togg leSwi t ch ( Termina to r ,  Gene ,  RBS ,  Promoter ,
Promoter , RBS , Gene , RBS , Repo r t e r , T e rm ina t o r ) ;
Rule r (
ON Togg leSwi t ch :
/ / Rule 1 and 2 : Rep r e s s i o n I n t e r a c t i o n s
Togg leSwi t ch [ 1 ] REPRESSES Togg leSwi t ch [ 4 ]
AND
Togg leSwi t ch [ 6 ] REPRESSES Togg leSwi t ch [ 3 ]
AND
/ / Rule 3 : D i f f e r e n t P romo te r s
Togg leSwi t ch [ 3 ] NOTEQUALS Togg leSwi t ch [ 4 ]
AND
/ / Rule 4 : We p r e f e r GFP as r e p o r t e r ( o p t i o n a l r u l e )
CONTAINS GFP
) ;
c o n s t r u c t [ ] l s t = p r o du c t ( ToggleSwi tch , 1000) ;
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5.6.3 Repressilator constructs
c o n s t r u c t R e p r e s s i l a t o r ( Promoter , RBS , Gene , Te rmina to r ,
Promoter , RBS , Gene , Te rmina to r , Promoter , RBS , Gene ,
Te rm ina t o r ) ;
Rule r (
ON R e p r e s s i l a t o r :
/ / REPRESSION r e l a t i o n s h i p s
R e p r e s s i l a t o r [ 2 ] REPRESSES R e p r e s s i l a t o r [ 4 ]
AND
R e p r e s s i l a t o r [ 6 ] REPRESSES R e p r e s s i l a t o r [ 8 ]
AND
R e p r e s s i l a t o r [ 1 0 ] REPRESSES R e p r e s s i l a t o r [ 0 ]
AND
pLux NOTMORETHAN 1
AND
pLtetO1 NOTMORETHAN 1
AND
lambdaPr NOTMORETHAN 1
AND
pLlacO1 NOTMORETHAN 1
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AND
rbs1 WITH rb s2 AND rb s2 WITH rb s3
) ;
c o n s t r u c t [ ] l s t = p r o du c t ( R e p r e s s i l a t o r , s t r i c t , 1000) ;
5.6.4 Transcriptional NOR-Gate constructs
c o n s t r u c t R e p r e s s i n g c o n s t r u c t ( Promoter , Promoter , RBS , Gene ,
Te rm ina t o r ) ;
c o n s t r u c t R e p o r t i n g c o n s t r u c t ( Promoter , RBS , Repo r t e r ,
T e rm ina t o r ) ;
c o n s t r u c t NorGate ( R e p r e s s i n g c o n s t r u c t , R e p o r t i n g c o n s t r u c t ) ;
Rule r (
ON NorGate :
/ / REPRESSES r e l a t i o n s h i p
R e p r e s s i n g c o n s t r u c t . Gene REPRESSES
R e p o r t i n g c o n s t r u c t . P romote r
AND
/ / d i f f e r e n t RBSs
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Re p r e s s i n g c o n s t r u c t . RBS NOTEQUALS R e p o r t i n g c o n s t r u c t
. RBS
AND
CONTAINS GFP
/ / d i f f e r e n t p r omo t e r s
AND
Re p r e s s i n g c o n s t r u c t [ 0 ] NOTEQUALS R e p r e s s i n g c o n s t r u c t
[ 1 ]
AND
Re p r e s s i n g c o n s t r u c t [ 1 ] NOTEQUALS R e p o r t i n g c o n s t r u c t .
P romote r
AND
/ / d i f f e r e n t T e rm i n a t o r s
CONTAINS T1 /∗∗AND CONTAINS T7∗∗ /
) ;
c o n s t r u c t [ ] l s t = p r o du c t ( NorGate , s t r i c t , 1000) ;
5.6.5 Invertase-based NOR-Gate constructs
c o n s t r u c t NorGate ( Promoter , I n v e r t a s e S i t e ,  Termina to r ,  
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I n v e r t a s e S i t e , I n v e r t a s e S i t e ,  Termina to r ,   I n v e r t a s e S i t e
, RBS , Repo r t e r , T e rm in a t o r ) ;
Rule r (
ON NorGate :
NorGate [ 1 ] MATCHES NorGate [ 3 ]
AND
NorGate [ 4 ] MATCHES NorGate [ 6 ]
AND
Bxb1_at tB WITH ph iC31_a t tB
) ;
c o n s t r u c t [ ] l s t = p r o du c t ( NorGate , s t r i c t , 1000) ;
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5.7 Algorithm
5.7.1 Algorithmic Flow
Users may interact with Raven at a variety of levels and degrees of complexity. At
the highest level, a user interacts with Raven by supplying a DNA parts library and a
set of constructs to be made from that library. Raven takes this input and produces a
set of assembly instructions which can be performed by either a human or computer user
(Figure 15a). After the plan has been attempted a number of times, some number of
the constructs and intermediates will be successfully cloned and some target constructions
might still be incomplete. The complete and incomplete constructs can be input back into
Raven, where a new plan with the updated library is generated. This cycle continues until
all target parts have been assembled.
At a lower level, the libraries and target constructs are uploaded into Raven and some
subset of the target constructs is selected to be assembledwith one of the supported assembly
methods (Figure 15b). Raven calculates an optimized assembly plan for these constructs
using the selected method and produces assembly instructions in the form of an assembly
graph and oligonucleotides necessary to implement the assembly plan. These instructions
are given in either human-readable or computer-readable format. A user may calculate
assembly plans for parts without specifying part sequences, but the oligo designs will be
incomplete and these oligos will need to be designed manually.
The algorithms have three major components: hierarchical step optimizations, overhang
assignment optimization and oligo-nucleotide design. The hierarchical cloning step plan
is the input for the overhang assignment algorithms and the complete graph with assigned
overhangs is the input for oligo design (Figure 15c). Optimizations are broken into these
three chunks to reduce computational complexity and serve as modular peices of the code
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base; the hierarchical step algorithms are common to all assembly methods, overhang
selection is common to some assembly methods and primer design is also common to some
methods.
Function 1 and Function 2 are illustrated in the flowchart presented in Figure 16.
Function 1 is concerned with creating the best single goal part solutions for all of the goal
parts in a loop adding the best solution to a growing list that is used to create the next best
solution until all graphs have been created. Function 2 deals with building the best single
goal part taking into account legal partitions of that goal part into subparts along with how
many of those subparts can be put together in any one reaction. This is a recursive calling
function where the single goal part is broken into these subparts with are themselves single
goal parts to solve. FunctionsminCostSlack, minCost, determineSlack, and combineGraphs
are helper functions for these two functions are not shown for clarity.
5.7.2 Definitions
- Let part P have an ID (string), composition(part)
- Let basicPart, bP, have composition.size() = 1
- Let goalPart, gP, have composition.size() > 1
- Each part in the composition of gP is a bP
- Given gP, an intermediatePart, iP, is any sequential subset of parts in the composition of
gP
- Given gP, there exists an optimal assemblyGraph aG, such that gP is assembled from bPs
to construct gP (and iPs)
- Given aG, all iPs within aG are assemblyIntermediates, aI
- aI are parts, iPs are not parts
- Given gP and aG, aI which must be in aG are requiredIntermediates, rqI
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- Given gP and aG, aI which must not be in aG are fobiddenIntermediates, fbI
- Given gP and aG, aI which are biased to be in aG are recommendedIntermediates, rcI
5.7.3 Pseudocode
The pseudocode is broken into four pieces: Multi-Goal-Part Algorithm, Multi-
-Goal-Part Algorithm Helper Methods, Overhang Assignment Algorithm, and Over-
hang Assignment Algorithm Helper Methods. This pseudocode provides an ab-
stracted description of the Raven source-code and covers the most critical Raven al-
gorithms and subroutines. Source code for the algorithms are also available online
(https://github.com/CIDARLAB/raven-public). None of the Raven UI code is detailed
and oligonucleotide design pseudocode is omitted, as it completes template designs for
each assembly method and optimizes according to nearest-neighbor melting temperature
methods and desired homology length. More sophisticated and optimized primer designs
are detailed in other work52.
5.7.4 Multi Goal Part Algorithm
This section covers the primary methods used to determine optimized solutions for
cloning steps for any number of goal parts under consideration. The multi-goal-part algo-
rithm considers a set of target constructs and initially determines the maximum number of
stages with which all constructs can be assembled. This number restricts the number of
stages all constructs will be assembled in and allows smaller constructs to be assembled
in more stages if they can share intermediate steps and thus reduce the total cloning step
count. The algorithm then determines the single-goal part cost for each individual construct
and saves the solution for the construct which scores best according to the multi-goal part
algorithm heuristics. This part is removed from the goal-part set and this process is repeated
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until all goal parts have optimized solutions.
The single-goal-part algorithm finds an optimized solution for assembling a construct
based upon our heuristic scores. This algorithm recursively explores the assembly space
for the construct in question by determining the cost of the intermediate constructs used to
assemble final constructs.
5.7.5 Multi Goal Part Algorithm Helper Methods
These helper methods describe the order of the scoring heuristics for the single-goal-part
algorithm and the way in which the space is explored. For each single goal part under
consideration, at least one solution for each allowed number of parts-per-reaction is explored
up to the specified upper limit, unless no such paths are possible. If specific intermediates
are forbidden, alternative paths are explored. Additional space is explored for parts in a
library which may be re-used that would not be considered on the default path.
5.7.6 Overhang Assignment Algorithm
Once the multi-goal-part algorithm has run and provided an optimized solution, this
graph is used as input for the overhang assignment algorithms. These algorithms vary across
assembly methods, but can be broken into three steps. In the first step, the rules of each
assembly method are applied. In most cases, this asserts that there can be no redundancy
of overhangs within a single cloning reaction - this would result in cloning reactions with
more than one selectable product. Once these restrictions are applied, all opportunities to
share overhangs in for all target constructs are optimized. For scarless assembly methods,
all overhangs are assumed to be unique unless a part is adjacent to the same two neighboring
parts in another instance and all parts are in the same orientation. For assembly methods
where all overhang regions are assumed to be the same, this step is also omitted. For
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assembly methods where this can be leveraged, sharing is optimized based upon part type
and orientation. In the final step, a library of parts is considered and a partial Cartesian
product is performed in an attempt to re-use as many parts from the parts library as possible
without violating steps one and two.
5.7.7 Overhang Assignment Algorithm Helper Methods
In these methods, special considerations are taken to maximize the sharing of overhangs
based on part type and orientation. Specifically, overhang sharing is maximized to include
sharing opportunities for part types that appear both on the forward and reverse strand.
5.7.8 Modular Overhang Site Selection
Overhang sites used byRaven are selected through a combination of experimental results
and a number of computational heuristics. We begin by generating a list of all 256 possible
4bp overhang sequences. From the full list of possible sequences, 12 sequences were
experimentally validated, and thus ranked as the top 12 sequences in the list of overhang.
The remaining sequences were then iteratively selected by using a scoring scheme that
incorporates a number of heuristics as well as traditional alignment methods. We generate
a score matrix for all pairwise alignments between the possible sequences. When selecting
the next overhang sequence, we sum the scores of a potential overhang sequence aligned to
all the sequences already selected. Next wemodulate the score of each potential sequence by
using heuristics to check for palindromes, monomeric runs, and GC content. The sequence
with the lowest score is selected. When a sequence is selected, its reverse complement
is also considered selected. In (Table 2), ‘‘*’’ indicates the reverse complement of a
sequence. Once this list is computed, it is stored as a static resource, which does not need
to be recomputed whenever Raven’s algorithms are used.
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5.8 In Silico Random Sampling Experimental Description
Construct Source # Best Un-Optimized Solutions
RFC 10 RFC 94 Gibson
Bonnet et al.26 6 5 | 42 | 21 3 | 37 | 58 2 | 7 | 34
Bonnet et al.27 13 5 | 73 | 23 4 | 98 | 127 2 | 24 | 55
Friedland et al.44 5 7 | 79 | 27 4 | 90 | 125 3 | 25 | 50
Lou et al.64 191 7 | 440 | 90 5 | 751 | 420 3 | 447 | 449
Moon et al.69 15 7 | 97 | 37 4 | 98 | 140 3 | 28 | 84
Suiti et al.91 23 6 | 111 | 19 4 | 187 | 255 3 | 59 | 97
Tabor et al.96 6 6 | 37 | 12 4 | 59 | 98 2 | 16 | 26
Tamsir et al.97 14 5 | 54 | 15 3 | 68 | 93 2 | 21 | 53
ALL 273 7 | 930 | 204 5 | 1497 | 907 4 | 674 | 844
Table 3: The single best un-optimized assembly scores for assembling constructs from the literature
discovered in the in silico experiments. Literature datasets are described by number of constructs
considered in each set. All solutions are reported in a ‘Cloning Stages | Cloning steps | PCR steps’
format.
To assess the quality of Raven’s solutions, we randomly sampled the solution space for
both our part junction assignment algorithm and our hierarchical assembly step algorithm,
conducting 1000 trials for each data point shown in Figure 11. To ensure that our results
were not biased by designs of a particular composition or size, we used Eugene to generate
a total of 5000 designs. These 5000 designs were based upon five well studied designs
published in the literature: the toggle switch47, repressilator40, invertase NOR gate91,
transcriptional NOR gate27, and DIC counter44. Given constraints specified by Eugene
rules, Eugene performs a Cartesian product for all the possibilities for each part position in
each construct design. The Eugene rules used are given in the Eugene Rules section of the
supplement and the 5000 constructs generated (1000 for each of the five construct designs)
are available separately as CSV files in Raven format. For more details about Raven format,
please visit ravencad.org.
Sampling the hierarchical algorithm effectively reduces to randomly sampling the space
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of partitioning each of the goal parts into cloning steps. For each experiment, we randomly
chose a subset of the 1000 constructs for each design (the number selected is shown on the
x-axis). For each of the randomly selected sets of goal parts, we partitioned it randomly,
pinning solutions so that part reuse can occur. Given that for a part of size n that can be
broken into m pieces, there would be
Pm
k=0

n
k

possible ways to partition the construct. And
so generating all possible partitions and then sampling from the set of all possible partitions
is computationally intractable. Instead, we used a geometric distribution to select the value.
The geometric distribution biases the selected number of partitions to favor a higher number;
this sampling behavior is appropriate given that one-pot reactions are frequently used to
assemble many parts at once. Once m is selected in constant time, the partition positions
can be generated in O(mn) time, which is trivial since m and n are usually fairly small.
The experiments for sampling the part junction assignment solution space followed a
procedure similar to the experiments for the hierarchical assembly step algorithm. For each
trial, the script again randomly select a subset of the 1000 constructs for each design. The
script constrained the number of steps and stages to be the same between each trial; the
hierarchical assembly step algorithm was used to determine the number of steps and stages.
After the number of steps and stages are computed, the part junction space was sampled. To
sample the part junction solution space, the first step of our overhang assignment algorithm
was reused, assigning abstract part junctions such that the assignment produced by random
sampling will be correct. Given n parts of roughly size m, there will be at most n(m+1)
different overhangs. For each and every partition junction, we enumerate from the first
possible assignment value until a valid assignment is reached, which we believe produces
the most intuitive naive assignment.
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5.9 PCR Verification and Cloning Efficiency
Raven’s algorithms assume that all PCR steps will be successfully executed and in cases
where a basic part is cloned into a vector, it will also be achieved without need for assembly
plan redesign. We verify that Raven-generated oligos produce successful PCRs for MoClo
assembly (Figure 17) and report the observed efficiency for all attempted cloning reactions.
Here, efficiency is calculated as the percentage of white colonies divided by the total number
of colonies on a plate after transformation of a MoClo cloning reaction.
Single-part cloning steps yielded the highest average cloning efficiency (72%), with
nearly 6-fold greater efficiency than six-part reactions (Figure 18). Overall, the cloning
efficiency had an approximately negative linear relationship with the number of parts cloned
in a single reaction. Using the observed average cloning efficiencies and extrapolating
efficiency from a linear regression of this trend for 3- and 4-part reactions as parameters
for the assembly plan, Raven calculates a plan with 3 additional steps, and 3 additional
PCR steps at an increased average efficiency of 14.4% (Figure 24) per cloning step, using
the observed efficiency values. This is an example of a case where observed efficiency
information can be interactively used within Raven to produce plans with higher average
efficiency at the expense of additional steps.
5.10 Raven Assembly Plans
5.10.1 Initial Plan
Raven assembly graphs are shown in a hierarchical format, with library parts at the
top and target parts at the bottom. The assembly graphs are organized by stages and
automatically generated by graphviz, using auto-generated SBOL-compliant glyphs from
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Pigeon (pigeoncad.org)23. The initial assembly plan (Figure 19) is generated assuming
equal efficiency for all reactions and a set of existing cloning vectors and template DNA.
Some existing vectors are used in the assembly plan.
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Figure 14: Runtime complexity of Raven algorithms. Raven’s twomain algorithmic components are
bound by n, the number of goal parts and m, the average number of basic parts per goal part, which
we show on the horizontal axis as the ‘‘Number of Parts in All Goal Parts", nm. The vertical axis
gives the approximate number of calculations according to conventional complexity analysis. Points
are shown to give the approximate number of operations required to calculate assembly plans for
all of the constructs from the publications shown in Table 1 and the number of operations required
to calculate 500 constructs of a design shown in Figure 2A. Separate curves are shown for the
hierarchical algorithm and the overhang assignment algorithm. Constructs from each publication
and constructs from each design in Figure 2A were calculated individually and then averaged over
all publications and designs respectively, giving the time shown in the legend. Note that the times
shown are approximations of realtime performance as times are machine and condition dependent
(Intel Xeon 2 x 6 core cpu, 24 GB RAM machine used to compute times).
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Figure 15: Raven flow charts (a) A user inputs their DNA library and set of target construct into
Raven, which generates assembly instructions. These assembly instructions are then implemented
and some constructs will be completed (yellow box) according to plan and some will not. These
incomplete constructs are input back into Raven for assembly redesign. (b) In the Raven UI, a
user inputs a DNA library and set of target construct and selects an assembly method with which
to construct a subset of the target constructs. Raven calculates an optimized assembly graph
and oligonucleotide designs necessary to execute the plan (black box) and generates human- or
computer-readable instruction files. (c) Raven optimizations are calculated in three major sequential
pieces: Hierarchical step optimization, overhang selection optimization and finally primer designs
for PCR steps. The sum of all these optimizations is an assembly graph and set of oligonucleotides
(black box).
79
Figure 16: The assembly algorithm is illustrated here as a set of two flowcharts. (A) presents the
initial function call to ‘‘createAsmGraph_mgp" (create assembly graph multiple-goal-parts). Here
a set of goal parts to be assembled is presented {gP} along with a parts library {PL}. Once that
set is empty #1 (all goal parts have been removed as their solutions are found), the function returns
(#2). Otherwise a low cost baseline is established (#3) and each goal part is explored (#4, #6,#7). If
a solution for a particular goal part results in a lower cost than the baseline, it becomes the baseline
(#8 and #9). Eventually all goal parts have been explored. The goal part with the lowest cost graph is
removed from the goal part set and its graph is added to the solutions (#5). The process repeats again
with the goal part solutions accumulating allowing their intermediate assemblies to be available for
subsequent solutions. The right hand side figure (B) illustrates the call to ‘‘createAsmGraph_sgp"
(create assembly graph single-goal-part). If the goal part already has a solution the function returns
(#10, #11). Otherwise legal indices to partition the single part into subparts are set up in #12. #13
and #14 demonstrate that once all parts per reaction (how many legal subparts) are explored, the
latest created graph is returned. #15, #16, and #17 illustrate that subpart divisions are explored
ultimately resulting in a recursive call to this same function with each of the legal divisions of this
part (#18). #19 illustrates the subpart solutions must be combined and that result compared with the
lowest discovered graph so far for this goal part. We refer the reader to both the pseudocode and the
open source code for more details.
80
Figure 17: PCR products for basic parts. Expected sizes (Left to Right) IR1_IR2_Term2|5|3*
178bp, loxP|1|3 62bp, flpe|3|m1 941bp, flpe|m1|5 392bp, IR1_IR2_Term2|0|3 178bp, cre|6|0 1093bp,
pTet|7|0 112bp, T1|4|8 133bp, pA1LacO|1|2* 105bp, pBAD|7|0 314bp, FRT|0|2 62bp, gfp|6|m2
652bp, gfp|m2|0 93bp, loxP|0|1 62bp, FRT|3*|0 62bp, pBAD|2|1 314bp, pBAD|1|2* 314bp, gfp|m2|4
93bp, gfp|2|m2 652bp
Figure 18: Average cloning efficiency as a function of parts per cloning reaction for MoClo (BBF
RFC 94). Measured average values marked with a triangle and error bars represent one standard
deviation.
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5.10.2 Redesigned Plans
Given the failed intermediates [pBAD|+, FRT|+, pBAD|-, rbs|+, flpe|+] and [pTet|+,
FRT|+, pBAD|-, rbs|+, flpe|+] in Figure 19 and the success of all other intermediate steps,
Raven can be leveraged to generate a new plan to complete the assembly of the target
constructs (Figure 24). In the calculation of this plan, all successful steps are added to the
library that can be used for assembly and the intermediates that failed are forbidden from
appearing in the redesigned solution. This revised solution required only 2 stages, 7 cloning
steps and 2 PCRs.
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The first plan redesign was also unsuccessful. Intermediate [pBAD|+, FRT|+, pBAD|-]
was not successful, but the other two intermediates were constructed successfully. Although
this intermediate did not express any coding sequences, it was hypothesized that this plasmid
creates too much transcriptional activity in a high copy plasmid.
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This second redesign was capable of producing all desired intermediates, but was not
successful in assembling the final constructs. We hypothesized that this was due to high
expression of recombinases in a high copy plasmid, similar to the problems experienced
in cloning the intermediates. To circumvent this problem, all intermediates and a bac-
terial aritificial chromosome (pBAC) backbone were digested, gel-extracted, and ligated
independently. These ligations, however did not produce any successful clones.
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The final redesign forced the creation of intermediates 12, 13, and 14, that accounted
for the entirety of the final constructs’ compositions, except for the leading promoter that
drives each construct’s function. Requiring an extra stage to build these constructs allowed
for a change in antibiotic resistance, so that there was no need for independent digestion,
gel extraction and ligation steps and also decreased the number of parts to be cloned in into
the pBAC backbone in the final cloning steps.
5.10.3 Biased Plans Outside Core Heuristics
If certain intermediate constructs are known to cause cloning difficulties outside of the
core Raven heuristics, these intermediates can be biased against using the Raven ‘discour-
aged’ markings. Intermediates marked as discouraged will be scored worse than otherwise
equivalent solutions with no discouraged intermediates. Alternatively, if a user is aware of
certain types of intermediates that are desirable outside of the Raven core heuristics, specific
intermediates may be ‘recommended’ in the Raven UI. Solutions with more recommended
intermediates will be scored higher than otherwise equivalent solutions.
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In the example of the genetic counter constructs, constitutive expression of recombinases
can cause significant difficulty in each cloning step. To avoid an assembly plan that contains
intermediates that might express recombinases, all such intermediates could be discouraged.
Specifically, the following intermediates can be explicitly discouraged in the Raven UI
to produce a MoClo solution for these constructs and these discouraged intermediates
(Figure 23):
-> pBAD|+, FRT|+, pBAD|-, dicRBS|+, flpe|+]
-> [pBAD|+, FRT|+, pBAD|-, dicRBS|+, flpe|+, IR1_IR2_TermT2|+]
-> [pBAD|+, FRT|+, pBAD|-, dicRBS|+, flpe|+, IR1_IR2_TermT2|+, FRT|-]
-> [pBAD|+, FRT|+, pBAD|-, dicRBS|+, flpe|+, IR1_IR2_TermT2|+, FRT|-, loxP|+]
-> [pBAD|+, FRT|+, pBAD|-, dicRBS|+, flpe|+, IR1_IR2_TermT2|+, FRT|-, loxP|+,
pBAD|-]
-> [pBAD|+, FRT|+, pBAD|-, dicRBS|+, flpe|+, IR1_IR2_TermT2|+, FRT|-, loxP|+, pBAD|-,
dicRBS|+]
-> [pBAD|+, FRT|+, pBAD|-, dicRBS|+, flpe|+, IR1_IR2_TermT2|+, FRT|-, loxP|+, pBAD|-,
dicRBS|+, gfp|+]
-> [pBAD|+, FRT|+, pBAD|-, dicRBS|+, flpe|+, IR1_IR2_TermT2|+, FRT|-, loxP|+, pBAD|-,
dicRBS|+, gfp|+, IR1_IR2_TermT2|+]
-> [pBAD|+, FRT|+, pBAD|-, dicRBS|+, flpe|+, IR1_IR2_TermT2|+, FRT|-, loxP|+, pBAD|-,
dicRBS|+, gfp|+, IR1_IR2_TermT2|+, loxP|-]
-> [pBAD|+, FRT|+, pBAD|-, dicRBS|+, flpe|+, IR1_IR2_TermT2|+, FRT|-, loxP|+, pBAD|-,
dicRBS|+, gfp|+, IR1_IR2_TermT2|+, loxP|-, dicRBS|+]
-> [pBAD|+, FRT|+, pBAD|-, dicRBS|+, flpe|+, IR1_IR2_TermT2|+, FRT|-, loxP|+, pBAD|-,
dicRBS|+, gfp|+, IR1_IR2_TermT2|+, loxP|-, dicRBS|+, gfp|+]
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-> [pBAD|+, FRT|+, pBAD|-, dicRBS|+, flpe|+, IR1_IR2_TermT2|+, FRT|-, loxP|+, pBAD|-,
dicRBS|+, cre|+]
-> [pBAD|+, FRT|+, pBAD|-, dicRBS|+, flpe|+, IR1_IR2_TermT2|+, FRT|-, loxP|+, pBAD|-,
dicRBS|+, cre|+, IR1_IR2_TermT2|+]
-> [pBAD|+, FRT|+, pBAD|-, dicRBS|+, flpe|+, IR1_IR2_TermT2|+, FRT|-, loxP|+, pBAD|-,
dicRBS|+, cre|+, IR1_IR2_TermT2|+, loxP|-]
-> [pBAD|+, FRT|+, pBAD|-, dicRBS|+, flpe|+, IR1_IR2_TermT2|+, FRT|-, loxP|+, pBAD|-,
dicRBS|+, cre|+, IR1_IR2_TermT2|+, loxP|-, dicRBS|+]
-> [pBAD|+, FRT|+, pBAD|-, dicRBS|+, flpe|+, IR1_IR2_TermT2|+, FRT|-, loxP|+, pBAD|-,
dicRBS|+, cre|+, IR1_IR2_TermT2|+, loxP|-, dicRBS|+, gfp|+]
-> [pTet|+, FRT|+, pBAD|-, dicRBS|+, flpe|+]
-> [pTet|+, FRT|+, pBAD|-, dicRBS|+, flpe|+, IR1_IR2_TermT2|+]
-> [pTet|+, FRT|+, pBAD|-, dicRBS|+, flpe|+, IR1_IR2_TermT2|+, FRT|-]
-> [pTet|+, FRT|+, pBAD|-, dicRBS|+, flpe|+, IR1_IR2_TermT2|+, FRT|-, loxP|+]
-> [pTet|+, FRT|+, pBAD|-, dicRBS|+, flpe|+, IR1_IR2_TermT2|+, FRT|-, loxP|+, pA1lacO|-
]
-> [pTet|+, FRT|+, pBAD|-, dicRBS|+, flpe|+, IR1_IR2_TermT2|+, FRT|-, loxP|+, pA1lacO|-
, dicRBS|+]
-> [pTet|+, FRT|+, pBAD|-, dicRBS|+, flpe|+, IR1_IR2_TermT2|+, FRT|-, loxP|+, pA1lacO|-
, dicRBS|+, cre|+]
-> [pTet|+, FRT|+, pBAD|-, dicRBS|+, flpe|+, IR1_IR2_TermT2|+, FRT|-, loxP|+, pA1lacO|-
, dicRBS|+, cre|+, IR1_IR2_TermT2|+]
-> [pTet|+, FRT|+, pBAD|-, dicRBS|+, flpe|+, IR1_IR2_TermT2|+, FRT|-, loxP|+, pA1lacO|-
, dicRBS|+, cre|+, IR1_IR2_TermT2|+, loxP|-]
-> [pTet|+, FRT|+, pBAD|-, dicRBS|+, flpe|+, IR1_IR2_TermT2|+, FRT|-, loxP|+, pA1lacO|-
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, dicRBS|+, cre|+, IR1_IR2_TermT2|+, loxP|-, dicRBS|+]
-> [pTet|+, FRT|+, pBAD|-, dicRBS|+, flpe|+, IR1_IR2_TermT2|+, FRT|-, loxP|+, pA1lacO|-
, dicRBS|+, cre|+, IR1_IR2_TermT2|+, loxP|-, dicRBS|+, gfp|+]
This plan takes 3 stages, 28 cloning steps and 33 PCR steps. This plan is a 1-cloning
step and 1-PCR step decrease from the initial plan and includes no intermediates capable
of expressing recombinases. This serves as an example where using recommended or
discouraged intermediates results in an approximately equivalent-cost solution that does
not include problematic intermedaites.
5.10.4 Efficiency-Optimized Plan
Using the measured average efficiency values from the implemented plans as a function
of parts-per-reaction, an alternative assembly plan can be considered that has additional
steps compared to the initial plan (Figure 19), but at higher average efficiency (i.e. more
steps with higher expected efficiency).
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5.10.5 Repressilator Constructs
The repressilator MoClo assembly plan (Figure 25) is generated assuming equal ef-
ficiency for all reactions not exceeding 4 parts per reaction and a set of existing cloning
vectors and DNA parts. No new vectors or Level 0 parts are created in this assembly plan, so
there are 0 PCR steps required. This plan leverages the CIDARMoClo Library, that already
contains each destination vector and Level 0 part required to create the repressilators.
Figure 25: MoClo assembly plan for Repressilator Constructs. (a) Assembly plan for six repressila-
tors with shared parts. (b) The intermediate constructs required to build the six repressilators shown
in (a). The green boxes indicate a successful assembly. (c) Assembly plan for one repressilator
using intermediates shown in (b) with the green boxes indicating the assembly was a success. (d) An
agarose gel (1% TAE) showing a restriction map for the repressilator shown in (c). Plasmid DNA
(1000 ng) was digested with SpeI enzyme (NEB). Lane M shows the molecular marker (2-log ladder
from NEB), lane 1 shows an empty Level 2 vector (2204bps), and lane 2 shows the insert containing
the repressilator (3304 bps; yellow box) cut out from its Level 2 vector backbone (2204 bps).
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Raven detected two previously undetected BbsI recognition sites in the lacI gene (se-
quence cloned from BBa_C0012), so these reactions (which contain a BbsI site) yielded
lower efficiencies than expectedwhen generating the final repressilators, which all contained
lacI. Despite this problem, two of the final six repressilators were assembled correctly.
While the lacI gene contains two BbsI sites, the 4 bps overhangs it produces do not match
the overhangs used in that cloning step so the final construct can still be generated, albeit at
a lower efficiency than normally observed for 4-part reactions (Figure 18).
5.11 Raven Human-Readable Assembly Instructions
Human-readable assembly instructions are generated automatically by Raven in an
output text-file format. The assembly files are organized by construct. For each construct,
the full set of assembly instructions is organized by stages. Assembly instructions tell the
user which overhangs each part is supposed to get and the direction of the parts within
each construct, intermediate and basic part. At the end of the file is all oligos that must be
ordered to construct all constructs in this selected assembly. These oligonucleotides are not
ordered by part or construct.
5.11.1 Initial Instructions for Counter Constructs
The following assembly file was used to implement the initial assembly plan for the
genetic counter constructs. The graphical plan associated with this plan is also shown
(Figure 19).
∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗
Assembly I n s t r u c t i o n s f o r t a r g e t p a r t : Coun te r4
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∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗
 > Assemble Coun te r4 | 7 | 8 | [ + , + ,   , + , + , + ,   , + ,   ,
+ , + , + ,   , + , + , +] by pe r f o rm ing a MoClo
c l o n i n g r e a c t i o n wi th : i n t e rm e d i a t e 2 | 7 | 5 | [ + , + ,   , + ,
+ ] , i n t e rm e d i a t e 1 | 5 | 6 | [ + ,   , + ,   , + ] , i n t e rm e d i a t e 3
| 6 | 8 | [ + , + ,   , + , + , + ] , DVL2 | 7 | 8
 > Assemble i n t e rm e d i a t e 5 | 7 | 5 | [ + , + ,   , + , +] by
pe r f o rm ing a MoClo c l o n i n g r e a c t i o n wi th : pTe t | 7 | 0 | [ + ] ,
FRT | 0 | 2 | [ + ] , pBAD | 2 | 1 | [   ] , dicRBS | 1 | 3 | [ + ] , f l p e | 3 | 5 | [ + ] ,
DVL1 | 7 | 5
 > Assemble i n t e rm e d i a t e 1 | 5 | 6 | [ + ,   , + ,   , +] by
pe r f o rm ing a MoClo c l o n i n g r e a c t i o n wi th : IR1_IR2_TermT2
| 5 | 3 ∗ | [ + ] , FRT | 3 ∗ | 0 | [   ] , loxP | 0 | 1 | [ + ] , pBAD | 1 | 2 ∗ | [   ] ,
dicRBS | 2 ∗ | 6 | [ + ] , DVL1 | 5 | 6
 > Assemble i n t e rm e d i a t e 3 | 6 | 8 | [ + , + ,   , + , + , +] by
pe r f o rm ing a MoClo c l o n i n g r e a c t i o n wi th : c r e | 6 | 0 | [ + ] ,
IR1_IR2_TermT2 | 0 | 3 | [ + ] , loxP | 3 | 1 | [   ] , dicRBS | 1 | 2 | [ + ] , g fp
| 2 | 4 | [ + ] , T1 | 4 | 8 | [ + ] , DVL1 | 6 | 8
97
 > Assemble pBAD | 7 | 0 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : pBAD | 7 | 0 | [ + ] , DVL0 | 7 | 0
 > Assemble FRT | 0 | 2 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : FRT | 0 | 2 | [ + ] , DVL0 | 0 | 2
 > Assemble pBAD | 2 | 1 | [   ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : pBAD | 2 | 1 | [   ] , DVL0 | 2 | 1
 > Assemble dicRBS | 1 | 3 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : dicRBS | 1 | 3 | [ + ] , DVL0 | 1 | 3
 > Assemble f l p e | 3 | 5 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : f l p e | 3 | 5 | [ + ] , DVL0 | 3 | 5
 > Assemble IR1_IR2_TermT2 | 5 | 3 ∗ | [ + ] by pe r f o rm ing a MoClo
c l o n i n g r e a c t i o n wi th : IR1_IR2_TermT2 | 5 | 3 ∗ | [ + ] , DVL0 | 5 | 3 ∗
 > Assemble FRT | 3 ∗ | 0 | [   ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : FRT | 3 ∗ | 0 | [   ] , DVL0 | 3 ∗ | 0
 > Assemble loxP | 0 | 1 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : loxP | 0 | 1 | [ + ] , DVL0 | 0 | 1
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 > Assemble pBAD | 1 | 2 ∗ | [   ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : pBAD | 1 | 2 ∗ | [   ] , DVL0 | 1 | 2 ∗
 > Assemble dicRBS | 2 ∗ | 6 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : dicRBS | 2 ∗ | 6 | [ + ] , DVL0 | 2 ∗ | 6
 > Assemble c r e | 6 | 0 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : c r e | 6 | 0 | [ + ] , DVL0 | 6 | 0
 > Assemble IR1_IR2_TermT2 | 0 | 3 | [ + ] by pe r f o rm ing a MoClo
c l o n i n g r e a c t i o n wi th : IR1_IR2_TermT2 | 0 | 3 | [ + ] , DVL0 | 0 | 3
 > Assemble loxP | 3 | 1 | [   ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : loxP | 3 | 1 | [   ] , DVL0 | 3 | 1
 > Assemble dicRBS | 1 | 2 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : dicRBS | 1 | 2 | [ + ] , DVL0 | 1 | 2
 > Assemble gfp | 2 | 4 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : g fp | 2 | 4 | [ + ] , DVL0 | 2 | 4
 > Assemble T1 | 4 | 8 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : T1 | 4 | 8 | [ + ] , DVL0 | 4 | 8
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PCR loxP wi th o l i g o s : o l i g o 1 and o l i g o 2 t o g e t p a r t : loxP
| 3 | 1 | [   ]
PCR IR1_IR2_TermT2 wi th o l i g o s : o l i g o 3 and o l i g o 4 t o g e t
p a r t : IR1_IR2_TermT2 | 0 | 3 | [ + ]
PCR loxP wi th o l i g o s : o l i g o 5 and o l i g o 6 t o g e t p a r t : loxP
| 0 | 1 | [ + ]
PCR FRT wi th o l i g o s : o l i g o 7 and o l i g o 8 t o g e t p a r t : FRT
| 0 | 2 | [ + ]
PCR c r e wi th o l i g o s : o l i g o 9 and o l i g o10 t o g e t p a r t : c r e
| 6 | 0 | [ + ]
PCR IR1_IR2_TermT2 wi th o l i g o s : o l i g o11 and o l i g o12 t o g e t
p a r t : IR1_IR2_TermT2 | 5 | 3 ∗ | [ + ]
Anneal o l i g o s : o l i g o13 and o l i g o14 t o g e t p a r t : dicRBS
| 2 ∗ | 6 | [ + ]
PCR T1 wi th o l i g o s : o l i g o15 and o l i g o16 t o g e t p a r t : T1
| 4 | 8 | [ + ]
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PCR gfp wi th o l i g o s : o l i g o17 and o l i g o18 t o g e t p a r t : g fp
| 2 | 4 | [ + ]
PCR pBAD wi th o l i g o s : o l i g o19 and o l i g o20 t o g e t p a r t : pBAD
| 2 | 1 | [   ]
PCR pBAD wi th o l i g o s : o l i g o21 and o l i g o22 t o g e t p a r t : pBAD
| 1 | 2 ∗ | [   ]
PCR f l p e wi th o l i g o s : o l i g o23 and o l i g o24 t o g e t p a r t : f l p e
| 3 | 5 | [ + ]
PCR FRT wi th o l i g o s : o l i g o25 and o l i g o26 t o g e t p a r t : FRT
| 3 ∗ | 0 | [   ]
PCR pBAD wi th o l i g o s : o l i g o27 and o l i g o28 t o g e t p a r t : pBAD
| 7 | 0 | [ + ]
Anneal o l i g o s : o l i g o29 and o l i g o30 t o g e t p a r t : dicRBS
| 1 | 2 | [ + ]
Anneal o l i g o s : o l i g o31 and o l i g o32 t o g e t p a r t : dicRBS
| 1 | 3 | [ + ]
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PCR lacZ wi th o l i g o s : o l i g o33 and o l i g o34 t o g e t v e c t o r :
DVL1 | 7 | 5
PCR lacZ wi th o l i g o s : o l i g o35 and o l i g o36 t o g e t v e c t o r :
DVL0 | 3 | 1
PCR lacZ wi th o l i g o s : o l i g o37 and o l i g o38 t o g e t v e c t o r :
DVL0 | 0 | 2
PCR lacZ wi th o l i g o s : o l i g o39 and o l i g o40 t o g e t v e c t o r :
DVL0 | 3 ∗ | 0
PCR lacZ wi th o l i g o s : o l i g o41 and o l i g o42 t o g e t v e c t o r :
DVL0 | 6 | 0
PCR lacZ wi th o l i g o s : o l i g o43 and o l i g o44 t o g e t v e c t o r :
DVL0 | 4 | 8
PCR lacZ wi th o l i g o s : o l i g o45 and o l i g o46 t o g e t v e c t o r :
DVL0 | 2 ∗ | 6
PCR lacZ wi th o l i g o s : o l i g o47 and o l i g o48 t o g e t v e c t o r :
DVL0 | 7 | 0
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PCR lacZ wi th o l i g o s : o l i g o49 and o l i g o50 t o g e t v e c t o r :
DVL1 | 6 | 8
PCR lacZ wi th o l i g o s : o l i g o51 and o l i g o52 t o g e t v e c t o r :
DVL0 | 2 | 4
PCR lacZ wi th o l i g o s : o l i g o53 and o l i g o54 t o g e t v e c t o r :
DVL0 | 1 | 3
PCR lacZ wi th o l i g o s : o l i g o55 and o l i g o56 t o g e t v e c t o r :
DVL0 | 1 | 2 ∗
PCR lacZ wi th o l i g o s : o l i g o57 and o l i g o58 t o g e t v e c t o r :
DVL0 | 0 | 3
PCR lacZ wi th o l i g o s : o l i g o59 and o l i g o60 t o g e t v e c t o r :
DVL0 | 5 | 3 ∗
PCR lacZ wi th o l i g o s : o l i g o61 and o l i g o62 t o g e t v e c t o r :
DVL2 | 7 | 8
∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗
Assembly I n s t r u c t i o n s f o r t a r g e t p a r t : Coun te r1
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∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗
 > Assemble Coun te r1 | 7 | 8 | [ + , + ,   , + , + , + ,   , + ,   ,
+ , + , + ,   , + , + , +] by pe r f o rm ing a MoClo
c l o n i n g r e a c t i o n wi th : i n t e rm e d i a t e 2 | 7 | 5 | [ + , + ,   , + ,
+ ] , i n t e rm e d i a t e 1 | 5 | 6 | [ + ,   , + ,   , + ] , i n t e rm e d i a t e 4
| 6 | 8 | [ + , + ,   , + , + , + ] , DVL2 | 7 | 8
 > Assemble i n t e rm e d i a t e 2 | 7 | 5 | [ + , + ,   , + , +] by
pe r f o rm ing a MoClo c l o n i n g r e a c t i o n wi th : pBAD | 7 | 0 | [ + ] ,
FRT | 0 | 2 | [ + ] , pBAD | 2 | 1 | [   ] , dicRBS | 1 | 3 | [ + ] , f l p e | 3 | 5 | [ + ] ,
DVL1 | 7 | 5
 > Assemble i n t e rm e d i a t e 1 | 5 | 6 | [ + ,   , + ,   , +] by
pe r f o rm ing a MoClo c l o n i n g r e a c t i o n wi th : IR1_IR2_TermT2
| 5 | 3 ∗ | [ + ] , FRT | 3 ∗ | 0 | [   ] , loxP | 0 | 1 | [ + ] , pBAD | 1 | 2 ∗ | [   ] ,
dicRBS | 2 ∗ | 6 | [ + ] , DVL1 | 5 | 6
 > Assemble i n t e rm e d i a t e 4 | 6 | 8 | [ + , + ,   , + , + , +] by
pe r f o rm ing a MoClo c l o n i n g r e a c t i o n wi th : g fp | 6 | 0 | [ + ] ,
IR1_IR2_TermT2 | 0 | 3 | [ + ] , loxP | 3 | 1 | [   ] , dicRBS | 1 | 2 | [ + ] , g fp
| 2 | 4 | [ + ] , T1 | 4 | 8 | [ + ] , DVL1 | 6 | 8
 > Assemble pBAD | 7 | 0 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : pBAD | 7 | 0 | [ + ] , DVL0 | 7 | 0
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 > Assemble FRT | 0 | 2 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : FRT | 0 | 2 | [ + ] , DVL0 | 0 | 2
 > Assemble pBAD | 2 | 1 | [   ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : pBAD | 2 | 1 | [   ] , DVL0 | 2 | 1
 > Assemble dicRBS | 1 | 3 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : dicRBS | 1 | 3 | [ + ] , DVL0 | 1 | 3
 > Assemble f l p e | 3 | 5 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : f l p e | 3 | 5 | [ + ] , DVL0 | 3 | 5
 > Assemble IR1_IR2_TermT2 | 5 | 3 ∗ | [ + ] by pe r f o rm ing a MoClo
c l o n i n g r e a c t i o n wi th : IR1_IR2_TermT2 | 5 | 3 ∗ | [ + ] , DVL0 | 5 | 3 ∗
 > Assemble FRT | 3 ∗ | 0 | [   ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : FRT | 3 ∗ | 0 | [   ] , DVL0 | 3 ∗ | 0
 > Assemble loxP | 0 | 1 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : loxP | 0 | 1 | [ + ] , DVL0 | 0 | 1
 > Assemble pBAD | 1 | 2 ∗ | [   ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : pBAD | 1 | 2 ∗ | [   ] , DVL0 | 1 | 2 ∗
105
 > Assemble dicRBS | 2 ∗ | 6 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : dicRBS | 2 ∗ | 6 | [ + ] , DVL0 | 2 ∗ | 6
 > Assemble gfp | 6 | 0 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : g fp | 6 | 0 | [ + ] , DVL0 | 6 | 0
 > Assemble IR1_IR2_TermT2 | 0 | 3 | [ + ] by pe r f o rm ing a MoClo
c l o n i n g r e a c t i o n wi th : IR1_IR2_TermT2 | 0 | 3 | [ + ] , DVL0 | 0 | 3
 > Assemble loxP | 3 | 1 | [   ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : loxP | 3 | 1 | [   ] , DVL0 | 3 | 1
 > Assemble dicRBS | 1 | 2 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : dicRBS | 1 | 2 | [ + ] , DVL0 | 1 | 2
 > Assemble gfp | 2 | 4 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : g fp | 2 | 4 | [ + ] , DVL0 | 2 | 4
 > Assemble T1 | 4 | 8 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : T1 | 4 | 8 | [ + ] , DVL0 | 4 | 8
PCR loxP wi th o l i g o s : o l i g o 1 and o l i g o 2 t o g e t p a r t : loxP
| 3 | 1 | [   ]
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PCR IR1_IR2_TermT2 wi th o l i g o s : o l i g o 3 and o l i g o 4 t o g e t
p a r t : IR1_IR2_TermT2 | 0 | 3 | [ + ]
PCR gfp wi th o l i g o s : o l i g o63 and o l i g o64 t o g e t p a r t : g fp
| 6 | 0 | [ + ]
PCR loxP wi th o l i g o s : o l i g o 5 and o l i g o 6 t o g e t p a r t : loxP
| 0 | 1 | [ + ]
PCR FRT wi th o l i g o s : o l i g o 7 and o l i g o 8 t o g e t p a r t : FRT
| 0 | 2 | [ + ]
PCR IR1_IR2_TermT2 wi th o l i g o s : o l i g o11 and o l i g o12 t o g e t
p a r t : IR1_IR2_TermT2 | 5 | 3 ∗ | [ + ]
Anneal o l i g o s : o l i g o13 and o l i g o14 t o g e t p a r t : dicRBS
| 2 ∗ | 6 | [ + ]
PCR T1 wi th o l i g o s : o l i g o15 and o l i g o16 t o g e t p a r t : T1
| 4 | 8 | [ + ]
PCR gfp wi th o l i g o s : o l i g o17 and o l i g o18 t o g e t p a r t : g fp
| 2 | 4 | [ + ]
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PCR pBAD wi th o l i g o s : o l i g o19 and o l i g o20 t o g e t p a r t : pBAD
| 2 | 1 | [   ]
PCR pBAD wi th o l i g o s : o l i g o21 and o l i g o22 t o g e t p a r t : pBAD
| 1 | 2 ∗ | [   ]
PCR f l p e wi th o l i g o s : o l i g o23 and o l i g o24 t o g e t p a r t : f l p e
| 3 | 5 | [ + ]
PCR FRT wi th o l i g o s : o l i g o25 and o l i g o26 t o g e t p a r t : FRT
| 3 ∗ | 0 | [   ]
PCR pBAD wi th o l i g o s : o l i g o27 and o l i g o28 t o g e t p a r t : pBAD
| 7 | 0 | [ + ]
Anneal o l i g o s : o l i g o29 and o l i g o30 t o g e t p a r t : dicRBS
| 1 | 2 | [ + ]
Anneal o l i g o s : o l i g o31 and o l i g o32 t o g e t p a r t : dicRBS
| 1 | 3 | [ + ]
PCR lacZ wi th o l i g o s : o l i g o49 and o l i g o50 t o g e t v e c t o r :
DVL1 | 6 | 8
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PCR lacZ wi th o l i g o s : o l i g o41 and o l i g o42 t o g e t v e c t o r :
DVL0 | 6 | 0
PCR lacZ wi th o l i g o s : o l i g o33 and o l i g o34 t o g e t v e c t o r :
DVL1 | 7 | 5
PCR lacZ wi th o l i g o s : o l i g o35 and o l i g o36 t o g e t v e c t o r :
DVL0 | 3 | 1
PCR lacZ wi th o l i g o s : o l i g o37 and o l i g o38 t o g e t v e c t o r :
DVL0 | 0 | 2
PCR lacZ wi th o l i g o s : o l i g o39 and o l i g o40 t o g e t v e c t o r :
DVL0 | 3 ∗ | 0
PCR lacZ wi th o l i g o s : o l i g o61 and o l i g o62 t o g e t v e c t o r :
DVL2 | 7 | 8
PCR lacZ wi th o l i g o s : o l i g o43 and o l i g o44 t o g e t v e c t o r :
DVL0 | 4 | 8
PCR lacZ wi th o l i g o s : o l i g o45 and o l i g o46 t o g e t v e c t o r :
DVL0 | 2 ∗ | 6
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PCR lacZ wi th o l i g o s : o l i g o47 and o l i g o48 t o g e t v e c t o r :
DVL0 | 7 | 0
PCR lacZ wi th o l i g o s : o l i g o51 and o l i g o52 t o g e t v e c t o r :
DVL0 | 2 | 4
PCR lacZ wi th o l i g o s : o l i g o53 and o l i g o54 t o g e t v e c t o r :
DVL0 | 1 | 3
PCR lacZ wi th o l i g o s : o l i g o55 and o l i g o56 t o g e t v e c t o r :
DVL0 | 1 | 2 ∗
PCR lacZ wi th o l i g o s : o l i g o57 and o l i g o58 t o g e t v e c t o r :
DVL0 | 0 | 3
PCR lacZ wi th o l i g o s : o l i g o59 and o l i g o60 t o g e t v e c t o r :
DVL0 | 5 | 3 ∗
∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗
Assembly I n s t r u c t i o n s f o r t a r g e t p a r t : Coun te r2
∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗
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 > Assemble Coun te r2 | 7 | 8 | [ + , + ,   , + , + , + ,   , + ,   ,
+ , + , + ,   , + , + , +] by pe r f o rm ing a MoClo
c l o n i n g r e a c t i o n wi th : i n t e rm e d i a t e 5 | 7 | 5 | [ + , + ,   , + ,
+ ] , i n t e rm e d i a t e 1 | 5 | 6 | [ + ,   , + ,   , + ] , i n t e rm e d i a t e 4
| 6 | 8 | [ + , + ,   , + , + , + ] , DVL2 | 7 | 8
 > Assemble i n t e rm e d i a t e 5 | 7 | 5 | [ + , + ,   , + , +] by
pe r f o rm ing a MoClo c l o n i n g r e a c t i o n wi th : pTe t | 7 | 0 | [ + ] ,
FRT | 0 | 2 | [ + ] , pBAD | 2 | 1 | [   ] , dicRBS | 1 | 3 | [ + ] , f l p e | 3 | 5 | [ + ] ,
DVL1 | 7 | 5
 > Assemble i n t e rm e d i a t e 1 | 5 | 6 | [ + ,   , + ,   , +] by
pe r f o rm ing a MoClo c l o n i n g r e a c t i o n wi th : IR1_IR2_TermT2
| 5 | 3 ∗ | [ + ] , FRT | 3 ∗ | 0 | [   ] , loxP | 0 | 1 | [ + ] , pBAD | 1 | 2 ∗ | [   ] ,
dicRBS | 2 ∗ | 6 | [ + ] , DVL1 | 5 | 6
 > Assemble i n t e rm e d i a t e 4 | 6 | 8 | [ + , + ,   , + , + , +] by
pe r f o rm ing a MoClo c l o n i n g r e a c t i o n wi th : g fp | 6 | 0 | [ + ] ,
IR1_IR2_TermT2 | 0 | 3 | [ + ] , loxP | 3 | 1 | [   ] , dicRBS | 1 | 2 | [ + ] , g fp
| 2 | 4 | [ + ] , T1 | 4 | 8 | [ + ] , DVL1 | 6 | 8
 > Assemble pBAD | 7 | 0 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : pBAD | 7 | 0 | [ + ] , DVL0 | 7 | 0
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 > Assemble FRT | 0 | 2 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : FRT | 0 | 2 | [ + ] , DVL0 | 0 | 2
 > Assemble pBAD | 2 | 1 | [   ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : pBAD | 2 | 1 | [   ] , DVL0 | 2 | 1
 > Assemble dicRBS | 1 | 3 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : dicRBS | 1 | 3 | [ + ] , DVL0 | 1 | 3
 > Assemble f l p e | 3 | 5 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : f l p e | 3 | 5 | [ + ] , DVL0 | 3 | 5
 > Assemble IR1_IR2_TermT2 | 5 | 3 ∗ | [ + ] by pe r f o rm ing a MoClo
c l o n i n g r e a c t i o n wi th : IR1_IR2_TermT2 | 5 | 3 ∗ | [ + ] , DVL0 | 5 | 3 ∗
 > Assemble FRT | 3 ∗ | 0 | [   ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : FRT | 3 ∗ | 0 | [   ] , DVL0 | 3 ∗ | 0
 > Assemble loxP | 0 | 1 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : loxP | 0 | 1 | [ + ] , DVL0 | 0 | 1
 > Assemble pBAD | 1 | 2 ∗ | [   ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : pBAD | 1 | 2 ∗ | [   ] , DVL0 | 1 | 2 ∗
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 > Assemble dicRBS | 2 ∗ | 6 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : dicRBS | 2 ∗ | 6 | [ + ] , DVL0 | 2 ∗ | 6
 > Assemble gfp | 6 | 0 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : g fp | 6 | 0 | [ + ] , DVL0 | 6 | 0
 > Assemble IR1_IR2_TermT2 | 0 | 3 | [ + ] by pe r f o rm ing a MoClo
c l o n i n g r e a c t i o n wi th : IR1_IR2_TermT2 | 0 | 3 | [ + ] , DVL0 | 0 | 3
 > Assemble loxP | 3 | 1 | [   ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : loxP | 3 | 1 | [   ] , DVL0 | 3 | 1
 > Assemble dicRBS | 1 | 2 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : dicRBS | 1 | 2 | [ + ] , DVL0 | 1 | 2
 > Assemble gfp | 2 | 4 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : g fp | 2 | 4 | [ + ] , DVL0 | 2 | 4
 > Assemble T1 | 4 | 8 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : T1 | 4 | 8 | [ + ] , DVL0 | 4 | 8
PCR loxP wi th o l i g o s : o l i g o 1 and o l i g o 2 t o g e t p a r t : loxP
| 3 | 1 | [   ]
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PCR IR1_IR2_TermT2 wi th o l i g o s : o l i g o 3 and o l i g o 4 t o g e t
p a r t : IR1_IR2_TermT2 | 0 | 3 | [ + ]
PCR gfp wi th o l i g o s : o l i g o63 and o l i g o64 t o g e t p a r t : g fp
| 6 | 0 | [ + ]
PCR loxP wi th o l i g o s : o l i g o 5 and o l i g o 6 t o g e t p a r t : loxP
| 0 | 1 | [ + ]
PCR FRT wi th o l i g o s : o l i g o 7 and o l i g o 8 t o g e t p a r t : FRT
| 0 | 2 | [ + ]
PCR IR1_IR2_TermT2 wi th o l i g o s : o l i g o11 and o l i g o12 t o g e t
p a r t : IR1_IR2_TermT2 | 5 | 3 ∗ | [ + ]
Anneal o l i g o s : o l i g o13 and o l i g o14 t o g e t p a r t : dicRBS
| 2 ∗ | 6 | [ + ]
PCR T1 wi th o l i g o s : o l i g o15 and o l i g o16 t o g e t p a r t : T1
| 4 | 8 | [ + ]
PCR gfp wi th o l i g o s : o l i g o17 and o l i g o18 t o g e t p a r t : g fp
| 2 | 4 | [ + ]
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PCR pBAD wi th o l i g o s : o l i g o19 and o l i g o20 t o g e t p a r t : pBAD
| 2 | 1 | [   ]
PCR pBAD wi th o l i g o s : o l i g o21 and o l i g o22 t o g e t p a r t : pBAD
| 1 | 2 ∗ | [   ]
PCR f l p e wi th o l i g o s : o l i g o23 and o l i g o24 t o g e t p a r t : f l p e
| 3 | 5 | [ + ]
PCR FRT wi th o l i g o s : o l i g o25 and o l i g o26 t o g e t p a r t : FRT
| 3 ∗ | 0 | [   ]
PCR pBAD wi th o l i g o s : o l i g o27 and o l i g o28 t o g e t p a r t : pBAD
| 7 | 0 | [ + ]
Anneal o l i g o s : o l i g o29 and o l i g o30 t o g e t p a r t : dicRBS
| 1 | 2 | [ + ]
Anneal o l i g o s : o l i g o31 and o l i g o32 t o g e t p a r t : dicRBS
| 1 | 3 | [ + ]
PCR lacZ wi th o l i g o s : o l i g o49 and o l i g o50 t o g e t v e c t o r :
DVL1 | 6 | 8
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PCR lacZ wi th o l i g o s : o l i g o41 and o l i g o42 t o g e t v e c t o r :
DVL0 | 6 | 0
PCR lacZ wi th o l i g o s : o l i g o33 and o l i g o34 t o g e t v e c t o r :
DVL1 | 7 | 5
PCR lacZ wi th o l i g o s : o l i g o35 and o l i g o36 t o g e t v e c t o r :
DVL0 | 3 | 1
PCR lacZ wi th o l i g o s : o l i g o37 and o l i g o38 t o g e t v e c t o r :
DVL0 | 0 | 2
PCR lacZ wi th o l i g o s : o l i g o39 and o l i g o40 t o g e t v e c t o r :
DVL0 | 3 ∗ | 0
PCR lacZ wi th o l i g o s : o l i g o61 and o l i g o62 t o g e t v e c t o r :
DVL2 | 7 | 8
PCR lacZ wi th o l i g o s : o l i g o43 and o l i g o44 t o g e t v e c t o r :
DVL0 | 4 | 8
PCR lacZ wi th o l i g o s : o l i g o45 and o l i g o46 t o g e t v e c t o r :
DVL0 | 2 ∗ | 6
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PCR lacZ wi th o l i g o s : o l i g o47 and o l i g o48 t o g e t v e c t o r :
DVL0 | 7 | 0
PCR lacZ wi th o l i g o s : o l i g o51 and o l i g o52 t o g e t v e c t o r :
DVL0 | 2 | 4
PCR lacZ wi th o l i g o s : o l i g o53 and o l i g o54 t o g e t v e c t o r :
DVL0 | 1 | 3
PCR lacZ wi th o l i g o s : o l i g o55 and o l i g o56 t o g e t v e c t o r :
DVL0 | 1 | 2 ∗
PCR lacZ wi th o l i g o s : o l i g o57 and o l i g o58 t o g e t v e c t o r :
DVL0 | 0 | 3
PCR lacZ wi th o l i g o s : o l i g o59 and o l i g o60 t o g e t v e c t o r :
DVL0 | 5 | 3 ∗
∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗
Assembly I n s t r u c t i o n s f o r t a r g e t p a r t : Coun te r6
∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗
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 > Assemble Coun te r6 | 7 | 8 | [ + , + ,   , + , + , + ,   , + ,   ,
+ , + , + ,   , + , + , +] by pe r f o rm ing a MoClo
c l o n i n g r e a c t i o n wi th : i n t e rm e d i a t e 5 | 7 | 5 | [ + , + ,   , + ,
+ ] , i n t e rm e d i a t e 6 | 5 | 6 | [ + ,   , + ,   , + ] , i n t e rm e d i a t e 3
| 6 | 8 | [ + , + ,   , + , + , + ] , DVL2 | 7 | 8
 > Assemble i n t e rm e d i a t e 5 | 7 | 5 | [ + , + ,   , + , +] by
pe r f o rm ing a MoClo c l o n i n g r e a c t i o n wi th : pTe t | 7 | 0 | [ + ] ,
FRT | 0 | 2 | [ + ] , pBAD | 2 | 1 | [   ] , dicRBS | 1 | 3 | [ + ] , f l p e | 3 | 5 | [ + ] ,
DVL1 | 7 | 5
 > Assemble i n t e rm e d i a t e 6 | 5 | 6 | [ + ,   , + ,   , +] by
pe r f o rm ing a MoClo c l o n i n g r e a c t i o n wi th : IR1_IR2_TermT2
| 5 | 3 ∗ | [ + ] , FRT | 3 ∗ | 0 | [   ] , loxP | 0 | 1 | [ + ] , pA1lacO | 1 | 2 ∗ | [   ] ,
dicRBS | 2 ∗ | 6 | [ + ] , DVL1 | 5 | 6
 > Assemble i n t e rm e d i a t e 3 | 6 | 8 | [ + , + ,   , + , + , +] by
pe r f o rm ing a MoClo c l o n i n g r e a c t i o n wi th : c r e | 6 | 0 | [ + ] ,
IR1_IR2_TermT2 | 0 | 3 | [ + ] , loxP | 3 | 1 | [   ] , dicRBS | 1 | 2 | [ + ] , g fp
| 2 | 4 | [ + ] , T1 | 4 | 8 | [ + ] , DVL1 | 6 | 8
 > Assemble pTet | 7 | 0 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : pTet | 7 | 0 | [ + ] , DVL0 | 7 | 0
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 > Assemble FRT | 0 | 2 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : FRT | 0 | 2 | [ + ] , DVL0 | 0 | 2
 > Assemble pBAD | 2 | 1 | [   ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : pBAD | 2 | 1 | [   ] , DVL0 | 2 | 1
 > Assemble dicRBS | 1 | 3 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : dicRBS | 1 | 3 | [ + ] , DVL0 | 1 | 3
 > Assemble f l p e | 3 | 5 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : f l p e | 3 | 5 | [ + ] , DVL0 | 3 | 5
 > Assemble IR1_IR2_TermT2 | 5 | 3 ∗ | [ + ] by pe r f o rm ing a MoClo
c l o n i n g r e a c t i o n wi th : IR1_IR2_TermT2 | 5 | 3 ∗ | [ + ] , DVL0 | 5 | 3 ∗
 > Assemble FRT | 3 ∗ | 0 | [   ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : FRT | 3 ∗ | 0 | [   ] , DVL0 | 3 ∗ | 0
 > Assemble loxP | 0 | 1 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : loxP | 0 | 1 | [ + ] , DVL0 | 0 | 1
 > Assemble pA1lacO | 1 | 2 ∗ | [   ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : pA1lacO | 1 | 2 ∗ | [   ] , DVL0 | 1 | 2 ∗
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 > Assemble dicRBS | 2 ∗ | 6 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : dicRBS | 2 ∗ | 6 | [ + ] , DVL0 | 2 ∗ | 6
 > Assemble c r e | 6 | 0 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : c r e | 6 | 0 | [ + ] , DVL0 | 6 | 0
 > Assemble IR1_IR2_TermT2 | 0 | 3 | [ + ] by pe r f o rm ing a MoClo
c l o n i n g r e a c t i o n wi th : IR1_IR2_TermT2 | 0 | 3 | [ + ] , DVL0 | 0 | 3
 > Assemble loxP | 3 | 1 | [   ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : loxP | 3 | 1 | [   ] , DVL0 | 3 | 1
 > Assemble dicRBS | 1 | 2 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : dicRBS | 1 | 2 | [ + ] , DVL0 | 1 | 2
 > Assemble gfp | 2 | 4 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : g fp | 2 | 4 | [ + ] , DVL0 | 2 | 4
 > Assemble T1 | 4 | 8 | [ + ] by pe r f o rm ing a MoClo c l o n i n g
r e a c t i o n wi th : T1 | 4 | 8 | [ + ] , DVL0 | 4 | 8
PCR loxP wi th o l i g o s : o l i g o 1 and o l i g o 2 t o g e t p a r t : loxP
| 3 | 1 | [   ]
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PCR IR1_IR2_TermT2 wi th o l i g o s : o l i g o 3 and o l i g o 4 t o g e t
p a r t : IR1_IR2_TermT2 | 0 | 3 | [ + ]
PCR loxP wi th o l i g o s : o l i g o 5 and o l i g o 6 t o g e t p a r t : loxP
| 0 | 1 | [ + ]
PCR FRT wi th o l i g o s : o l i g o 7 and o l i g o 8 t o g e t p a r t : FRT
| 0 | 2 | [ + ]
PCR c r e wi th o l i g o s : o l i g o 9 and o l i g o10 t o g e t p a r t : c r e
| 6 | 0 | [ + ]
PCR IR1_IR2_TermT2 wi th o l i g o s : o l i g o11 and o l i g o12 t o g e t
p a r t : IR1_IR2_TermT2 | 5 | 3 ∗ | [ + ]
Anneal o l i g o s : o l i g o13 and o l i g o14 t o g e t p a r t : dicRBS
| 2 ∗ | 6 | [ + ]
PCR T1 wi th o l i g o s : o l i g o15 and o l i g o16 t o g e t p a r t : T1
| 4 | 8 | [ + ]
PCR gfp wi th o l i g o s : o l i g o17 and o l i g o18 t o g e t p a r t : g fp
| 2 | 4 | [ + ]
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PCR pBAD wi th o l i g o s : o l i g o19 and o l i g o20 t o g e t p a r t : pBAD
| 2 | 1 | [   ]
PCR f l p e wi th o l i g o s : o l i g o23 and o l i g o24 t o g e t p a r t : f l p e
| 3 | 5 | [ + ]
PCR FRT wi th o l i g o s : o l i g o25 and o l i g o26 t o g e t p a r t : FRT
| 3 ∗ | 0 | [   ]
Anneal o l i g o s : o l i g o29 and o l i g o30 t o g e t p a r t : dicRBS
| 1 | 2 | [ + ]
PCR pTet wi th o l i g o s : o l i g o65 and o l i g o66 t o g e t p a r t : pTet
| 7 | 0 | [ + ]
PCR pA1lacO wi th o l i g o s : o l i g o67 and o l i g o68 t o g e t p a r t :
pA1lacO | 1 | 2 ∗ | [   ]
Anneal o l i g o s : o l i g o31 and o l i g o32 t o g e t p a r t : dicRBS
| 1 | 3 | [ + ]
PCR lacZ wi th o l i g o s : o l i g o61 and o l i g o62 t o g e t v e c t o r :
DVL2 | 7 | 8
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PCR lacZ wi th o l i g o s : o l i g o35 and o l i g o36 t o g e t v e c t o r :
DVL0 | 3 | 1
PCR lacZ wi th o l i g o s : o l i g o37 and o l i g o38 t o g e t v e c t o r :
DVL0 | 0 | 2
PCR lacZ wi th o l i g o s : o l i g o39 and o l i g o40 t o g e t v e c t o r :
DVL0 | 3 ∗ | 0
PCR lacZ wi th o l i g o s : o l i g o33 and o l i g o34 t o g e t v e c t o r :
DVL1 | 7 | 5
PCR lacZ wi th o l i g o s : o l i g o41 and o l i g o42 t o g e t v e c t o r :
DVL0 | 6 | 0
PCR lacZ wi th o l i g o s : o l i g o43 and o l i g o44 t o g e t v e c t o r :
DVL0 | 4 | 8
PCR lacZ wi th o l i g o s : o l i g o45 and o l i g o46 t o g e t v e c t o r :
DVL0 | 2 ∗ | 6
PCR lacZ wi th o l i g o s : o l i g o49 and o l i g o50 t o g e t v e c t o r :
DVL1 | 6 | 8
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PCR lacZ wi th o l i g o s : o l i g o51 and o l i g o52 t o g e t v e c t o r :
DVL0 | 2 | 4
PCR lacZ wi th o l i g o s : o l i g o53 and o l i g o54 t o g e t v e c t o r :
DVL0 | 1 | 3
PCR lacZ wi th o l i g o s : o l i g o57 and o l i g o58 t o g e t v e c t o r :
DVL0 | 0 | 3
PCR lacZ wi th o l i g o s : o l i g o55 and o l i g o56 t o g e t v e c t o r :
DVL0 | 1 | 2 ∗
PCR lacZ wi th o l i g o s : o l i g o47 and o l i g o48 t o g e t v e c t o r :
DVL0 | 7 | 0
PCR lacZ wi th o l i g o s : o l i g o59 and o l i g o60 t o g e t v e c t o r :
DVL0 | 5 | 3 ∗
∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗
5.12 Interactive Assembly Summary
Because it is not feasible for a human to design hundreds or thousands of assembly plans
manually and even more difficult to produce efficient and low-cost solutions for such sets,
a computational tool to automatically determine these solutions is needed. And because
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assembly planning instructions are necessary for liquid-handling robots and microfluidics
to perform high throughput cloning and other automation techniques, the absence of an
automated method to inform a robot which steps to take to assemble genetic constructs
would severely limit the automation power of a larger tool pipeline.
Raven generates experimentally valid assembly plans, and, although it cannot guarantee
success of any one plan or complete target sequence, it can generate new plans on the basis
of some specific step failures and efficiency data. While these algorithms have the ability to
incorporate feedback of reaction failures and successes to produce better solutions, they do
not provide any methodology for predicting the success or failure of specific assembly steps
or the construct’s function. It is important to note that some standardized cloning protocols
cannot be rigidly implemented to clone all constructs owing to inherent complexity of
function of the constructs under consideration: some cloning challenges still must be solved
by amending standard protocols and thus fall outside the purview of a protocol-agnostic
assembly plan.
Finally, formal assembly files can be used to capture assembly information from pre-
viously attempted assemblies. The documentation of cloning reaction success and failure
and of the path to successful assembly can be accumulated and allow easier reproduction
of published work. This is particularly important because this information is often poorly
documented, which hinders the ability to build on previous work. Formally documented
assembly planning provides a better avenue for tracking this information, and previously
attempted assemblies could be studied to develop new heuristics and bring further insight
to popular molecular cloning methods.
Raven currently supports only six highly used, well-defined cloning methods, but ad-
ditional systematic biases and constraints outside the tool’s core heuristics can be applied
to Raven’s solutions by specifying forced, forbidden, recommended and discouraged in-
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termediates and specific cloning vectors. Moreover, the principles of this approach could
be expanded and further generalized to nearly to any cloning method, provided common
sub-problem scoring required by dynamic programming. The generality of the algorithmic
solutions and the breadth of the permitted inputs allow assembly solutions to be adapted to
potentially any DNA assembly method because Raven broadly suggests how to reuse DNA
libraries to build a set of genetic constructs.
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6 Automated Data Analysis and Simulation
The second type of instructions produced by Phoenix are instructions that define a
set of experimental measurements to make upon a set of strains with their corresponding
constructs. This file is a simple CSV file with columns for strain, environmental conditions,
time and indication of controls to be used in analysis. The final column in this file is for
a cytometry file name that was recorded for the strain, environmental condition and time
specified for that row.
This ‘key file’ represents all of the data acquired in one set of functional measurement
experiments. A Phoenix user receives this key file along with the Raven assembly instruc-
tions to build and test constructs. These files are protocol-agnostic (i.e. they do not include
detailed information on reagent quantity to be added to each reaction and growth conditions),
but a set of default protocols will be made available on the Phoenix website.
6.1 Data Acquisition
With these instructions and default protocols, a user has a complete plan for building
and testing all necessary constructs for that phase in the design hierarchy. While these
testing instructions are protocol agnostic to allow for some flexibility in laboratory set-up,
minor variations in cloning reaction and testing experiment set-up can have consequences
in the experimental outcomes.
While Raven can guarantee that its assembly plannings are valid in terms of assembly
steps and stages and assigned flanking sequences, it cannot guarantee that any particular
plan will be successful. Sometimes it may be necessary for a user to change some aspects of
the assembly plan to build all target constructs. One of the key assumptions of the functional
testing is that strains with identical genetic information should perform the same in each
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laboratory setting. If this assumption is true, readings acquired on each flow cytometer must
still be normalized. To perform this normalization, we require users to run Speherotech
RCP-30-5A 8-peak rainbow calibration beads to normalize data acquired on each machine
to an absolute unit for all channels - molecules of equivalent fluorescein (MEFL). Finally,
Phoenix instructs users to grow cells to saturation in luria broth (LB) from a plated colony
and then re-innoculated from that culture into minimal media plus glucose to grow to
log-phase growth before measurement. These defined growth conditions reduce variation
in measurement.
6.2 Data Analysis
After all constructs are built and tested, the user is responsible for returning the key file
indicating which strain, environmental condition, and time each raw data file corresponds to.
This file and a folder containing the raw data are interpreted by an analysis script written inR,
using the Bioconductor packages to process the cytometry files. This script first parses the
key file to identify unique rows and replicate data rows to determine all unique time points
and environmental conditions for each strain. Duplicate rows are considered experimental
replicates - three replicates are standard, but there are no limitations on providing more
replicates.
Each set of replicates is processed in the following way: First, only channels that are
controlled for with a positive control are considered, all other channels except forward
and side scatter are discarded. Next, the spectral overlap matrix is calculated using the
fluorescent protein positive controls and a negative control. After this step, an elliptical
gate is created for forward and side scatter to remove cells that are outliers in size and
shape and then all readings with negative values are removed. Next, for the remaining
populations, spectral overlap correction is performed with the spectral overlap matrix. After
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this correction, a clustering algorithm for identifying the largest cluster of readings in each
channel is run and the mean values of these clusters for each channel is collected. As a final
step, readings from the negative control processed in the same analytics flow are subtracted
from all samples to correct for auto-fluorescence.
This processed meta-data is used to create plots in the R console and the data points
are exported in a CSV file for input into Phoenix. Phoenix associates these values to an
experiment object associated with each plasmid.
6.3 Simulation for Parameter Estimation and Compositional Designs
This processed meta-data is used to estimate the rate constants needed for each EX-
PRESSEE and EXPRESSOR. For EXPRESSORs, the steady-state expression measurement
is used with the measured degradation rate of its added testing component, gfp or bfp to fit
to a steady-state expression constant.
For EXPRESSEEs, experimental data is used to determine two or three rate constants
(depending on the regulator). The degradation rate of each EXPRESSEE and degradation
control construct is measured by adding the transcriptional inhibitor, chloramphenicol to
the environment at time t = 0 to inhibit protein expression. With protein expression stopped,
a time-series measurement for fluorescence can be used to determine the degradation pa-
rameters. To fit the regulation constant, a titration for the inducer controlling the expression
of the EXPRESSEE is performed and the regulation constant is determined with parameter
estimation. To determine the small molecule interaction constant for EXPRESSEEs that are
sensitive to small molecule inducers, another parameter estimation is run for the fluores-
cence produced by the regulation control as a function of the small molecule present in the
environment.
These paramater estimations are performed with an open-source simulation tool called
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COPASI. Once the parameter values for each EXPRESSEE and EXPRESSOR are estimated,
kinetic models for compositional designs can be simulated. These simulations are also
performed with COPASI 53 and the resulting simulation traces are returned to Phoenix,
where they are evaluated against functional specifications.
6.4 Structural Failure Mode Grammars
The simulated compositional traces are thenmodel-checked against an STL specification
and evaluated for robustness. The most robust simulated compositions are selected and
subsequently returned to the user for building and testing. Sometimes, this first round
of simulation may align very well with experimental results, but other times it may not.
In cases where the simulations and experimental results do not align, it is important to
have a mechanisms for probing into why the disagreement occurred and to learn from this
information to make better selections from future simulations.
The fourth chapter of this thesis discussed how grammars can be applied to validate
a structural specification. It is also possible to use grammars in the context of types of
structural motifs that are often the source of particular design failures. In Phoenix, me and
my colleagues defined 10 types of common failure modes and wrote grammars in ANTLR77
to determine which failure modes exist in any given structure.
When a design’s experimental data does not match its simulation, Phoenix identifies
which failure modes are present and based upon the specific disagreement in traces, in-
structs the creation of additional constructs to test which failure mode. The results of this
experimental inquiry are stored in Phoenix as design rules documenting which particular
sequence combinations resulted in failures and avoids making similar design selections for
future designs.
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7 Data Visualization, Documentation and Storage
After experimental data is processed and used for simulation, it is important to store
information in a database and effectively visualize the results to a user. In a synthetic
synthetic biology workflow, this includes information related to design, DNA assembly
and testing for each plasmid. This task involves determining the correct information to
store, determining the best tool for storing this information and then determining the most
informative data to display back to a user.
7.1 Data Storage and Management
Since biological data is typically large and multi-dimensional, it is important to de-
termine which type of information is important to store in a database and which type of
database is the most appropriate. In synthetic biology, there is no existing consensus on
which information is essential and which is optional, although some groups have put signifi-
cant effort into trying to establish these standards45. There are also a number of open-source
repositories for synthetic biological part information, but there is little agreement on which
data standard to adopt.
For my tools, I opted to use Clotho as my data storage tool. The reasons for using this
tool as opposed to other options was threefold: 1. Clotho has a well thought-out core data
model, but is intentionally flexible to amendments to the data model. 2. Most of my other
tools, including Phoenix are Java based like Clotho, so there is a smooth data transfer and
3. Since it was developed in the same research group, I can occasionally contribute as a
developer to the functionality of the tool and easily tailor functionality with others on the
Phoenix development team.
After I decided to use Clotho as the database tool, it needed to be determined exactly
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what type of information to store. In general, I opted to store plasmid sequences, feature
annotation information, design information, metadata for assembly, testing, and simulation.
This is because only the metadata is used for key decision making and can be automatically
regenerated from raw data or other metadata. Similarly, images from generated plots are not
saved because they can be reproduced automatically. The next challenge was to determine
which metadata and sequence information to return to users of my tools.
7.2 Electronic Datasheet Generator for Data Visualization
In other engineering fields such as electrical engineering, researchers use electronic
datasheets to accomplish this task for electronic transistors. In recent years, synthetic biol-
ogists have thought about employing similar approaches to documenting and representing
information related to their plasmids41 to help biologists evaluate parts for use in composi-
tional designs. Since there currently exist few tools for automatically creating datasheets,
me and my colleagues decided to develop a tool to do this. The ‘alpha version’ of this tool,
called Owl was tailored towards information contained in the iGEM Registry of Standard
Biological parts and could query the Registry to fill out a datasheet partially. The current
‘beta version’ is more general and can be amended to query arbitrary fields from multiple
data sources and organize the information by type of information and uses LATEXstyle files
to typeset the document.
The Registry of Standard Biological Parts (http://parts.igem.org) is the largest open–
source registry for synthetic biological parts. It is also the standard registry for the annual
iGEM. As iGEM expands, many new entries and entry modifications are submitted each
year. Given this already large and rapidly growing registry and other growing registries
of synthetic genetic parts (JBEI https://registry.jbei.org/, JGI http://genome.jgi.doe.gov/,
SynBERC registry.synberc.org, and BioFAB www.biofab.org), the question of how to best
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share and store data becomes very important to answer. It is critical that the synthetic biol-
ogy community forms a concerted effort to share data on genetic parts and other biological
components in a standard way.15
The Registry purposefully allows flexibility in the entries in both format and content,
lending itself to a broad diversity of parts. One of the Registrys strengths is its ability
to capture many types of synthetic biological parts, but it lacks consistent formatting and
presentation that is required for machine readability and manual comparisons. The lack
of a common format can also hinder new users and may impede them from adding useful
information to the Registry. Furthermore, as a variety of software tools becomes available
for biodesign automation, it is necessary to provide a unified format for a part datasheet so
that the tools can leverage data stored in these sheets.
To address these problems, me and my colleagues created an online tool called Owl
(www.owlcad.org) to generate electronic datasheets automatically, with a common format.
This version ofOwl (alpha) lays the groundwork for the automated generation of datasheets.
7.2.1 An Electronic Datasheet Generator - Alpha Version
Owl (www.owlcad.org) is a web-based tool that generates electronic datasheets for
synthetic biological parts. A datasheet provides a quantitative and qualitative description of
genetic device behavior that allows an engineer to determine if a part is suitable for a desired
use29. Owl allows users to enter part information either automatically from pre-existing
entries on the Registry or manually in the user interface. Owl currently uses Synthetic
Biology Open Language visual (SBOLv) compliant images for part and device images and
can link images from Pigeon23 (www.pigeoncad.org) and Raven14 (www.ravencad.org)
onto a datasheet. Owl generates HTML pages in a standard format and can be saved as a
PDF.
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In consideration of previous datasheets15,41 and common assays used to characterize
biological systems, Owl datasheets are separated into five sections: (1) Basic Information,
for part identification and visual representation; (2) Designer Information, for attributing
authorship, providing contact information and the date; (3) Design Details, for detailed
information about part function; (4) Assembly Information, for describing how the part was
made; and (5) Assays, for presenting characterization data. We have provided three sections
for assays: restriction mapping, flow cytometry, and a section where users can add their
own type of assay.
To demonstrate Owl’s ability to represent a diversity of parts, we created several
example datasheets for a variety of functionally different parts (datasheets are available
online at www.owlcad.org). These datasheets represent several parts created by the
CIDAR lab (www.cidarlab.org) as well as examples from literature to demonstrate Owls
applicability to a diverse assortment of parts.
Required and Optional Fields
Owl datasheets have required fields based on the Registrys data model (Figure 26).
This information is meant to represent the minimum information required to define a part
with which data can be experimentally associated. Specifically, Owl requires that a DNA
part be described sufficiently such that an assay could be performed upon it. Thus, all fields
needed to describe a parts composition are required. Owl datasheets have five required
fields, namely: Part Name, Sequence, Part Summary, Author(s), and Date. Completion of
all other relevant fields is encouraged but optional.
Automated Population of Fields from Registry Pages
When generating a new datasheet from an existing Registry page, Owl parses informa-
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Figure 26: The Owl UI sections for Basic Information, Designer Information, Design Details, and
Assembly Information. The input fields for each section are outlined on the left with descriptions
for the input information for each field. The images on the right show the web interface UI from
www.owlcad.org.
tion from the Registrys XML pages and autopopulates fields on the datasheet, namely: Part
Name (ex: BBa B0034), Part Description, Part Type (ex: RBS), Date entered, Part Author,
and Sequence. The user can then go through each section manually and add to or change
the existing information.
While Owl’s goal is to automate the creation of datasheets, the task inherently poses
the question of what a datasheet for synthetic biological parts should display. The default
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format of Owl’s datasheet may not be ideal for all cases; however, it is flexible and provides
fields similar to those described in previouswork15,41 such as identifying information, circuit
visualization, author contact information, assembly information, and characterization by gel
electrophoresis andflowcytometry. Further considerations include the ability to present four
kinds of data proposed in previouswork:(4) static behavior, dynamic behavior, compatibility
with other devices, and reliability of the device measured by the number of generations the
device can uphold desired functionality.
7.2.2 An Electronic Datasheet - Beta Version
The initial release of the Alpha version of Owl received two key points of feedback: 1.
It is too restrictive of the data types - a user with additional data fields might not fit into the
categories defined in the first release. 2. It only searches the Registry of Parts and can only
search for a small set of fields.
Although the initial tool was designed to be partially restrictive to ensure that a minimal
amount of information was entered on each datasheet, it seemed that we had not struck the
right balance between data requirements and flexibility. This was also the reason that only a
small number of fields were searchable from the Registry of Parts. It was important that the
next version of Owl be integrated with additional platforms and registries45,101 to generate
datasheets automatically as a user moves through experimental workflows.
To address these concerns, theOwl development team created editable, human-readable
‘‘configuration files" that can be modified for custom fields and wells with a limited set of
data types. Since the stylistic formatting of the datasheets may not suit all users, editable
style files are be used to automatically typeset datasheets. Owl was also extended to search
custom fields in existing repositories. Finally, a Java API was created so that Owl can be
linked more easily with other tools outside of the Phoenix environment.
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Datasheets produced with the beta version can accomplish all of the same functionalities
of the alpha version with the exception of explicit required fields. The thinking here is that
other tools that link in with Owl can enforce internal null checks and this was not important
to include explicitly in the this tool.
7.3 Design Tree Visualization
In large design hierarchies, it is important for a user to visualize where they currently
stand in the process and which existing plasmids have data and which do not. In Phoenix,
this is represented in the user interface as a collapsible tree that represents all of the nodes
in a decomposed design. At any one of these nodes, the user can click on nodes or set of
nodes to view electronic datasheets produced by Owl.
Figure 27: Screenshot of a design tree created by decomposing an input design in Phoenix
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7.4 Data Visualization Summary
Owl is intended to serve the community by streamlining the creation of electronic
datasheets that can be used to exchange important biological part information in a visually
intuitive and user-friendly manner. Although other platforms formalize data exchange
between machine users45, there is a need for a consistently structured way to present data to
a human user with which they can make decisions. I believe that Owl can help fill this gap.
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8 Workflow Test Cases and Results
To validate that the overall Phoenix tool function, it was important to apply it to a set
of example specifications. To do this, we built and tested a set of all EXPRESSORs and
EXPRESSEEs for the functional terminals (‘NOT gate’, ‘toggle switch’, and ‘oscillator’)
for our sequence feature library.
8.1 Unit testing of ‘Classic’ Networks
A unit test is a unit of work done upon a system to individually and independently
scrutinize a single assumption about the behavior of that unit of work. In a genetic unit
test, we define the single assumptions to be the enzymatic model for each node and the
enzymatic parameters corresponding to each individual sequence. Thus, Phoenix adds
testing components to perform unit tests to measure these parameters. In Phoenix, there are
two general classes of unit tests - unit tests for EXPRESSORs and EXPRESSEs and unit tests
for functional elements and complex function created with multiple functional elements.
Unit tests for EXPRESSORs and EXPRESSEEs are performed for creating the base
characterization data for fitting enzymatic model parameters. Since EXPRESSORs are
measured to estimate their expression parameter, an expression unit test is performed.
Expression unit tests require steady-state fluorescence expression tests and a degradation unit
test for each fluorescent protein expressed by the EXPRESSOR. Degradation unit tests are
performed by adding chloramphenicol to liquid culture at time t = 0 to inhibit expression via
transcriptional inhibition and measuring fluorescence over time. EXPRESSEEs necessitate
unit tests for degradation, regulation, and (when appropriate) small molecule interaction.
Regulation unit tests require inducing the expression of an EXPRESSEE with an inducible
upstream promoter to measuring how the expression of a transciptional unit controlled
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by the promoter the EXPRESSEE regulates changes as a function of the amount of the
EXPRESSEE present. We design these tests by building an additional regulation control
plasmid and co-transforming it with the EXPRESSEE plasmid. These regulation control
plasmids are built separately to save cloning cost and minimize failure mode opportunities
in measurement. Small molecule unit tests are performed for EXPRESSEEs that are known
to interact with a specific small molecule. For this test, a high quantity of the EXPRESSEE
is induced and a titration curve of the small molecule is performed and measured over time.
For our library of 8 promoter-regulator pairs, 6 RBSs, 10 fluorescent proteins, 8 ter-
minator and 2 vectors, I used Phoenix to decompose the designs and return the set of
EXPRESSORs and EXPRESSEEs for a ‘forward-strand only’ linear design architecture.
Figure 28: Preliminary data from expression tests for EXPRESSORs and degradation, regulation,
and small molecule tests for EXPRESSEEs.
For the EXPRESSORs, I observed variable sequence and function outcomes, which
agreed with our team’s findings in the multiplex assembly experiments described in Chapter
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5.
Since the peptide linker sequences used in the EXPRESSEEs between the regulator and
fluorescent protein had not yet been validated, I had to determine if these linker peptides
interfered with the function of either the regulator or the fluorescent protein. It proved to
be the case that the linker peptide we employed in the Phoenix workflow worked for nearly
all EXPRESSEEs, so my colleagues and I advanced to measuring the EXPRESSEEs for
their degradation, regulation and small molecule constants. These measurements resulted
in a range of parameter values (data not shown in this document), so our group concluded
that we had a rich design space of EXPRESSORs and EXPRESSEEs and used the fitted
parameters to combinatorially simulate our specification targets.
Unit tests for compositional designs are based upon the functional specification as
opposed to expert knowledge of the structural elements. For these cases, a test is done for
time and performance bounds of the specification. Unit tests are performed at each node in
the design tree for which there is a compositional design.
8.2 Building Networks via ‘Brute Force’
To determine to what degree Phoenix’s computational methods improve outcomes, it
was important to compare the success of these part assignments against a set of constructs
that use the same assemblymethod and part arrangements, but with randomly assigned parts.
To do this, I used the same ARGNs for the linear design architecture for the ‘NOT gate’,
‘toggle switch’ and ‘oscillator’ and determined all possible partially-assigned constructs
where I only selected the promoter-regulator pairs to remain orthogonal where appropriate.
Using these valid, partially-assigned GRNs, I multiplexed the the remaining components of
the GRN to build randomly-assigned networks. The results of these tests are not presented
in this document, but will be used as a baseline to compare against Phoenix-designed
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networks in future work.
8.3 Unit-testing Failure Modes
Since the initial set of assignments were all in the same linear arrangements, they were
all subject to the same failure mode - transcriptional read-through. To test the wider scope
of defined failure modes, we built and tested ‘NOT gates’, ‘toggle switches’ and ‘oscillators’
with non-linear arrangements.
Figure 29: Arrangements for two-transcriptional unit constructs that present different common
failure modes. (a) The linear arrangement is sensitive to transcriptional red-through from the first
transcriptional unit into the second. (b) The alternating-strand transcriptional unit architecture
introduce a supercoiling failure mode created by adjacent promoters. (c) This arrangement exposes
the failure mode of transcriptional interference where polymerases on either strand might collide
during transcription and affect expression.
For two-transcriptional-unit constructs such as these, there are a total of 12 valid ar-
rangements based upon our structural grammar. To test more of these arrangements, we
selected three more different types of architectures and used these as input to build alter-
native sets of EXPRESSORs that expose different types of failure modes. The outcomes
of these functional tests demonstrated that different structural part arrangements with the
same sequences yielded different expression rates, but the data for these experiments are
not detailed in this document.
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9 Project Summary and Impact
9.1 Project Summary
This thesis explores questions of what types of project should be built with synthetic
biology and describes a set of software tools and workflows for accomplishing these project
goals for genetic regulatory networks in E. coli. I described a project in which we probe a
variety of projects for risk assessment and biosecurity concerns and then described another
project that examined a project that poses problems of risk and biosecurity in detail. In the
rest of the chapters, I discussed my technical work in building two software tools to solve
specific sub-problems in the software tool space, namely Raven for creating assembly plans
and Owl for creating electronic datasheets. The rest of this thesis describes the creation
of Phoenix, a tool that ties together many existing software tools for specific tasks of a
synthetic biology workflow in addition to providing algorithmic solutions to a number of
unsolved sub-problems in the workflow.
9.2 Impact of Work
Phoenix represents one of the first closed-loop workflow tools in the synthetic biology
space to automate a majority of design decisions in genetic regulatory network creation
via experimental instructions and data entry. In contrast to other existing software suites,
Phoenix is not designed as an open canvas where a user has flexibility to create nearly any
type of genetic network, but still has to make all design decisions manually. Rather, the
ultimate goal of Phoenix is to advance the goals of the bio-design automation community
and work towards powerful computer-aided design that simplifies the design process for a
user and enables higher level of design abstraction.
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It is well known that creating synthetic genetic regulatory networks is no easy task
and some would agree that many aspects of manual synthetic biology methodologies have
already reached or will soon reach their limits - it will not be possible to solve significantly
more complex problems without computational tools and computer-aided design. The
central goal of this thesis is to make significant progress on this front and open the door to
larger design goals while instituting a philosophy of careful consideration of which projects
to pursue.
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10 Methods
10.1 Computational
Back-end algorithms in all of the tools in this thesis were implemented in Java. The
Raven, Owl, and Phoenix UIs were implemented in Javascript using jQuery and Bootstrap
libraries. Scripts for recommended, discouraged and required parts in Raven are imple-
mented in Eugene24. Design tree graphs in Phoenix are generated using d3.js libraries
and automatically-generated construct glyphs are made from scripts to pigeoncad.org23.
Analytics scripts are implemented R and rely heavily on the Bioconductor packages.
10.2 Experimental
10.2.1 Materials
Cloning enzymes and buffers ordered from New England Biolabs, Ipswich, MA, USA
and Promega Corporation, Madison, WI, USA. Epoch kits and protocols used to extract
and prepare DNA. Oligonucleotides synthesized by IDT. DIC counter plasmid templates
acquired from Timothy Lu. All reactions performed in an Eppendorf Mastercycler ep
thermocylcer (Eppendorf North America, Westbury, NY, USA).
10.2.2 MoClo DNA Assembly
10.2.3 Cloning Destination Vectors
The lacZ fragment was PCR amplified from a lacZ-containing cloning vector
(pMJS2AF, donated by Michael Smanski) and subsequently cloned into three backbones,
depending on theMoClo level: level 0 used pSB1A2, level 1 used pSB1K3, and level 2 used
145
pSB1A2. DNA containing the lacZ fragment was used as template for PCR reactions.
PCR reactions with 5X Phusion HF Buffer, 100 uM dNTPs, Phusion DNA Polymerase,
5% DMSO, 1 mM MgCl2 (New England Biolabs, Ipswich, MA, USA), and sterile diH2O.
Reactions were performed using the following parameters: one denaturation step at 95C
for 5 min, followed by 30 extension cycles (95 C 20 sec., 61 C 20 sec., 72 C 15 sec.), a
final 5 min extension step at 72 C and then incubation at 4 C. PCR products over 100bp
were purified using either the QIAquick PCR Purification Kit (Qiagen Inc., Valencia, CA,
USA) or GenCatch PCR Purification Kit (Epoch Life Sciences, Sugar Land, TX, USA)
according to the manufacturer’s protocol. PCR products and pSB1K3 and pSB1A2 vectors
were digested with SpeI enzyme (NEB) according to the manufacturer’s protocol using up
to 500 ng DNA. Restriction digestions were purified using the QIAquick PCR Purification
Kit (Qiagen) following the manufacturer’s protocol. Ligation reactions were performed
with T4 DNA ligase (NEB) following the manufacturer’s protocol with a 3:1 insert part to
vector backbone ratio.
10.2.4 PCR Amplifying Level 0 Parts
Level 0 target sequences over 32 bps were PCR amplified from the DIC 3-Counter
multiple-inducer (Donated by Timothy Lu). Level 0 sequences for parts smaller than 34
bps, annealing oligonucleotides were designed and annealed with the following parameters:
95 C for 3 min, then 55 x (-1 C every 30 sec.), then incubation at 4 C. (see Supplementary
Raven files for part sequences). Reactions were performed using the following parameters:
one denaturation step at 95 C for 5 min, followed by 30 extension cycles (95 C 20 sec.,
61 C 20 sec., 72 C 30 sec.), a final 5 min. extension step at 72 C and then held at 4 C.
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10.2.5 MoClo Cloning Protocol
Each MoClo reaction had the following contents: 40 fmol of each DNA component
(DNA PCR Product or previously madeMoClo DNA Parts, and the appropriate Destination
Vector), BsaI or BbsI (BsaI for Level 1, BbsI for Level 0 and Level 2; NEB), high concentra-
tion T4 DNA ligase (C M1794, Promega, Madison, WI, USA), 1 X T4 DNA Ligase Buffer
(Promega), and sterile, diH2O. Reactions performed using the following parameters: 25-35
cycles (37 C 1.5 min., 16 C 3 min.), followed by 50 C for 5 minutes and 80 C for 10
minutes and then held at 4 C until transformed. Level 0 reactions were done for 25 cycles
while Level 1 and 2 reactions were done for 25-30 cycles. Transformations into Alpha
Select Gold Efficiency E. coli cells (Bioline USA Inc., Taunton, MA, USA), DH5-Z1, and
epi300 competent E. coli. Transformations were heat shocked at 42 C for 45 sec. and
recovered in SOC media for 1 hour at 37 C, 300rpm.
10.2.6 Primer Design
Primers for MoClo99 assembly designed in the following format for parts larger than 24
bp: NN - BpiI recognition site - NN - 1234 - part - 5768 - NN - BpiI recognition site - NN.
Forward primers: 50 NN - GAAGAC - NN - [Overhang Sequence] - [first 24 bp of part] 30.
Reverse primers: 50 [last 24bps of gene] - [Overhang Sequence] - NN - GTCTTC - NN 30.
For parts smaller than 24bp, annealing primers were designed that adhere to the preceding
format.
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